zbh-8k_20201106.htm

0001564590-20-051650.txt : 20201106 0001564590-20-051650.hdr.sgml : 20201106 20201106064529 ACCESSION NUMBER: 0001564590-20-051650 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20201106 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201106 DATE AS OF CHANGE: 20201106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZIMMER BIOMET HOLDINGS, INC. CENTRAL INDEX KEY: 0001136869 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 134151777 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16407 FILM NUMBER: 201292344 BUSINESS ADDRESS: STREET 1: 345 EAST MAIN STREET CITY: WARSAW STATE: IN ZIP: 46580 BUSINESS PHONE: 5742676131 MAIL ADDRESS: STREET 1: 345 EAST MAIN STREET CITY: WARSAW STATE: IN ZIP: 46580 FORMER COMPANY: FORMER CONFORMED NAME: ZIMMER HOLDINGS INC DATE OF NAME CHANGE: 20010315 8-K 1 zbh-8k_20201106.htm 8-K zbh-8k_20201106.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2020

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-16407	13-4151777
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

345 East Main Street

Warsaw, Indiana 46580

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (574) 267-6131

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	ZBH	New York Stock Exchange
1.414% Notes due 2022	ZBH 22A	New York Stock Exchange
2.425% Notes due 2026 1.164% Notes due 2027	ZBH 26 ZBH 27	New York Stock Exchange New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 2.02Results of Operations and Financial Condition.

On November 6, 2020, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2020. The press release is attached hereto as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

The information contained in Item 2.02 of this report, including Exhibit 99.1 hereto, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

EXHIBIT INDEX
Exhibit No.		Description
99.1 104		Press release dated November 6, 2020 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 6, 2020

	ZIMMER BIOMET HOLDINGS, INC.

	By:	/s/ Chad F. Phipps
	Name:	Chad F. Phipps
	Title:	Senior Vice President, General Counsel and Secretary

EX-99.1 2 zbh-ex991_6.htm EX-99.1 zbh-ex991_6.htm

345 E. Main St.
Warsaw, IN 46580
www.zimmerbiomet.com	Exhibit 99.1

Media	Investors
Meredith Weissman	Keri Mattox
(703) 346-3127	(215) 275-2431
meredith.weissman@zimmerbiomet.com	keri.mattox@zimmerbiomet.com

	Ezgi Yagci
	(617) 549-2443
	ezgi.yagci@zimmerbiomet.com

Zimmer Biomet Announces Third Quarter 2020 Financial Results

•

Third quarter net sales of $1.929 billion increased 2.0%, and increased 1.1% on a constant currency basis

•

Third quarter diluted earnings per share were $1.16; adjusted diluted earnings per share were $1.81

(WARSAW, IN) November 6, 2020 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2020. The Company reported third quarter net sales of $1.929 billion, an increase of 2.0% over the prior year period, and an increase of 1.1% on a constant currency basis. Net earnings for the third quarter were $242.5 million. Net earnings on an adjusted basis were $376.8 million.

Diluted earnings per share were $1.16 for the third quarter, a decrease of 44.2% from the prior year period. Adjusted diluted earnings per share were $1.81 for the third quarter, an increase of 2.3% over the prior year period.

“While the stronger than expected recovery of elective procedures in the third quarter was encouraging, we also remain focused on ZB’s strong operational execution, which continues to drive confidence in our underlying business," said Bryan Hanson, President and CEO of Zimmer Biomet. "It is important to note that the challenges and fluidity around COVID-19 persist as we move into the end of the year. Still, we will continue to transform our business, invest for greater value and prioritize innovation to better position the Company for accelerated growth over the long term. I am so proud of our global team for the support we provide healthcare professionals and patients every day and our ongoing commitment to the ZB mission to better the lives of people around the world."

Page 1 of 25

While the recovery from COVID-19 continued in the third quarter, the pace of procedure volume and patient returns slowed toward the end of the period, with overall performance still negatively impacted by the pandemic. Stronger recovery was seen in the Americas and Asia Pacific in the quarter, with a slower return in regions within Europe, the Middle East and Africa (EMEA).

Please see the attached schedules accompanying this press release for additional details on performance in the quarter, including sales by Zimmer Biomet’s three geographies and five product categories.

Recent Highlights

Aligned with Zimmer Biomet’s active portfolio management strategy and the ongoing transformation of the business, the Company has invested in priority and right-to-win areas to drive long-term growth, including two recently completed acquisitions. Collectively, these deals total approximately $80 million in initial spend and up to $98 million in deferred and milestone payments and add new or soon-to-be launched product offerings to the Zimmer Biomet portfolio:

•

Incisive LLC, a privately-held operating room (OR) solutions company in the expanding $1.2 billion global integrated OR market; Incisive’s technology drives efficiency in the surgical setting through a comprehensive offering of ”smart OR” infrastructure, including surgical booms and lights with a smaller footprint as well as proprietary data analytics and artificial intelligence capabilities; this approach reduces acquisition and construction costs and is especially attractive to ambulatory surgery center (ASC) customers; revenues will be recorded in the Company’s S.E.T. segment

•

Relign Corp., a privately-held company in the attractive and growing $1.6 billion arthroscopy market and overall $5 billion sports medicine market; Relign’s offerings include the consolidation of three differentiated arthroscopy tower components into a single system, a first in the industry, and address a key portfolio gap for Zimmer Biomet in the sports medicine and broader ASC markets; revenues will be recorded in the Company’s S.E.T. segment

Page 2 of 25

Geographic and Product Category Sales

The following sales tables provide results by geography and product category for the three and nine-month periods ended September 30, 2020, as well as the percentage change compared to the prior year periods, on both a reported basis and a constant currency basis.

NET SALES - THREE MONTHS ENDED SEPTEMBER 30, 2020
(in millions, unaudited)


							Constant
	Net						Currency
	Sales		% Change				% Change
Geographic Results
Americas	$	1,216.5		3.2		%		3.3		%
EMEA		366.2		(2.3	)			(5.7	)
Asia Pacific		346.6		2.3				0.7
Total	$	1,929.3		2.0		%		1.1		%
Product Categories
Knees
Americas	$	402.6		0.9		%		0.9		%
EMEA		126.6		(6.4	)			(9.5	)
Asia Pacific		119.5		1.7				(0.1	)
Total		648.7		(0.5	)			(1.4	)
Hips
Americas		268.6		7.9				8.0
EMEA		109.7		0.8				(2.6	)
Asia Pacific		105.8		4.4				2.9
Total		484.1		5.4				4.4
S.E.T *		359.9		3.3				2.5
Dental, Spine & CMFT**		295.5		7.3				6.5
Other		141.1		(10.3	)			(11.1	)
Total	$	1,929.3		2.0		%		1.1		%


* Sports Medicine, Extremities and Trauma
** Craniomaxillofacial and Thoracic

Page 3 of 25

NET SALES - NINE MONTHS ENDED SEPTEMBER 30, 2020
(in millions, unaudited)


							Constant
	Net						Currency
	Sales		% Change				% Change
Geographic Results
Americas	$	3,051.5		(14.9	)	%		(14.8	)	%
EMEA		983.0		(23.0	)			(22.7	)
Asia Pacific		904.7		(8.8	)			(9.0	)
Total	$	4,939.2		(15.7	)	%		(15.6	)	%
Product Categories
Knees
Americas	$	1,003.9		(17.9	)	%		(17.9	)	%
EMEA		344.5		(27.4	)			(27.0	)
Asia Pacific		304.3		(13.6	)			(13.4	)
Total		1,652.7		(19.4	)			(19.2	)
Hips
Americas		671.8		(10.3	)			(10.2	)
EMEA		291.9		(20.6	)			(20.4	)
Asia Pacific		282.7		(7.0	)			(7.2	)
Total		1,246.4		(12.3	)			(12.2	)
S.E.T *		946.1		(10.9	)			(10.8	)
Dental, Spine & CMFT**		729.7		(14.7	)			(14.7	)
Other		364.3		(22.2	)			(22.2	)
Total	$	4,939.2		(15.7	)	%		(15.6	)	%


* Sports Medicine, Extremities and Trauma
** Craniomaxillofacial and Thoracic

Cash Flow and Balance Sheet

Cash provided by operating activities for the third quarter was $381.3 million and free cash flow was $287.2 million. At September 30, 2020, the Company had $967.3 million in cash and cash equivalents on the balance sheet. In the third quarter, the Company paid $49.6 million in dividends and declared a dividend of $0.24 per share. As previously announced, Zimmer Biomet refinanced $1.5 billion in debt that came due April 1, 2020, renegotiated the terms of its $1.5 billion revolver and secured an additional $1.0 billion credit facility. No borrowings are outstanding under these credit facilities.

Financial Guidance

While Zimmer Biomet saw encouraging recovery in elective procedures during the third quarter, there continues to be uncertainty around the scope and duration of COVID-19 and its ongoing impact. Therefore, the Company is currently unable to quantify the expected impact on its results of operations, financial condition and cash flows, which could be material, for 2020 and is not providing fourth quarter financial guidance at this time.

Page 4 of 25

Conference Call

The Company will conduct its third quarter 2020 investor conference call today, November 6, 2020, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be archived for replay following the conference call.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Website Information

We routinely post important information for investors on our website, www.zimmerbiomet.com, in the “Investor Relations” section. We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

Note on Non-GAAP Financial Measures

This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

Page 5 of 25

Sales change information for the three and nine-month periods ended September 30, 2020 is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases.

Net earnings (loss) and diluted earnings (loss) per share for the three and nine-month periods ended September 30, 2020 are presented on a GAAP (reported) basis and on an adjusted basis. Adjusted earnings and adjusted diluted earnings per share exclude the effects of certain inventory and manufacturing-related charges including charges to discontinue certain product lines; intangible asset amortization; goodwill and intangible asset impairment; restructuring and other cost reduction initiative expenses; quality remediation expenses; acquisition, integration and related expenses; certain litigation gains and charges; expenses to establish initial compliance with the European Union Medical Device Regulation; other charges; any related effects on our income tax provision associated with these items; tax adjustments relating to the impacts of tax only amortization in Switzerland; the effect of Switzerland tax reform; other certain tax adjustments; and, with respect to earnings per share information, provide for the effect of dilutive shares assuming net earnings in a period of a reported net loss.

Free cash flow is an additional non-GAAP measure that is presented in this press release. Free cash flow is computed by deducting additions to instruments and other property, plant and equipment from net cash provided by operating activities.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release. This press release also contains supplemental reconciliations of additional non-GAAP financial measures that the Company presents in other contexts. These additional non-GAAP financial measures are computed from the most directly comparable GAAP financial measure as indicated in the applicable reconciliation.

Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the Company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures. In addition, constant currency sales changes, adjusted operating profit, adjusted diluted earnings per share and free cash flow are used as performance metrics in our incentive compensation programs.

Page 6 of 25

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the impact of the COVID-19 pandemic on our business, and any statements about our forecasts, expectations, plans, intentions, strategies or prospects. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: the effects of the COVID-19 global pandemic and other adverse public health developments on the global economy, our business and operations and the business and operations of our suppliers and customers, including the deferral of elective procedures and our ability to collect accounts receivable; the risks and uncertainties related to our ability to successfully execute our restructuring plans; the success of our quality and operational excellence initiatives, including ongoing quality remediation efforts at our Warsaw North Campus facility; the ability to remediate matters identified in inspectional observations or warning letters issued by the U.S. Food and Drug Administration (FDA), while continuing to satisfy the demand for our products; compliance with the Deferred Prosecution Agreement entered into in January 2017; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; the ability to retain the independent agents and distributors who market our products; dependence on a limited number of suppliers for key raw materials and outsourced activities; the possibility that the anticipated synergies and other benefits from mergers and acquisitions will not be realized, or will not be realized within the expected time periods; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management’s attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the FDA and foreign government regulators, such as more stringent requirements for regulatory clearance of products; the outcome of government investigations; competition; pricing pressures; changes in customer demand for our products and services caused by demographic changes or other factors; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors and cost containment efforts of healthcare purchasing organizations; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our

Page 7 of 25

products and services; supply and prices of raw materials and products; control of costs and expenses; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries. A further list and description of these risks and uncertainties and other factors can be found in our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and our subsequent filings with the Securities and Exchange Commission (SEC). Copies of these filings are available online at www.sec.gov, www.zimmerbiomet.com or on request from us. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.

###

Page 8 of 25


ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, except per share amounts, unaudited)

	2020			2019
Net Sales	$	1,929.3		$	1,892.4
Cost of products sold, excluding intangible asset amortization		569.4			535.7
Intangible asset amortization		149.7			146.6
Research and development		85.9			114.4
Selling, general and administrative		790.0			826.4
Restructuring and other cost reduction initiatives		16.2			5.4
Quality remediation		9.8			20.7
Acquisition, integration and related		9.1			(2.6	)
Operating expenses		1,630.1			1,646.6
Operating Profit		299.2			245.8
Other income (expense), net		10.6			(4.4	)
Interest expense, net		(54.0	)		(56.8	)
Earnings before income taxes		255.8			184.6
Provision (benefit) for income taxes		9.7			(247.4	)
Net Earnings		246.1			432.0
Less: Net earnings attributable to noncontrolling interest		3.6			0.9
Net Earnings of Zimmer Biomet Holdings, Inc.	$	242.5		$	431.1
Earnings Per Common Share
Basic	$	1.17		$	2.10
Diluted	$	1.16		$	2.08
Weighted Average Common Shares Outstanding
Basic		207.1			205.3
Diluted		208.5			207.0

Page 9 of 25


ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, except per share amounts, unaudited)

	2020			2019
Net Sales	$	4,939.2		$	5,856.5
Cost of products sold, excluding intangible asset amortization		1,481.0			1,670.4
Intangible asset amortization		445.0			436.9
Research and development		272.0			328.2
Selling, general and administrative		2,283.9			2,461.6
Goodwill and intangible asset impairment		645.0			70.1
Restructuring and other cost reduction initiatives		89.2			17.0
Quality remediation		35.9			63.1
Acquisition, integration and related		15.7			8.5
Operating expenses		5,267.7			5,055.8
Operating (Loss) Profit		(328.5	)		800.7
Other income (expense), net		17.4			(9.6	)
Interest expense, net		(158.9	)		(174.5	)
(Loss) earnings before income taxes		(470.0	)		616.6
Provision (benefit) for income taxes		1.2			(193.5	)
Net (Loss) Earnings		(471.2	)		810.1
Less: Net earnings (loss) attributable to noncontrolling interest		1.4			(0.8	)
Net (Loss) Earnings of Zimmer Biomet Holdings, Inc.	$	(472.6	)	$	810.9
(Loss) Earnings Per Common Share
Basic	$	(2.29	)	$	3.96
Diluted	$	(2.29	)	$	3.93
Weighted Average Common Shares Outstanding
Basic		206.8			204.8
Diluted		206.8			206.3

Page 10 of 25

ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, unaudited)

	September 30,		December 31,
	2020		2019
Assets
Cash and cash equivalents	$	967.3	$	617.9
Receivables, net		1,340.7		1,363.9
Inventories		2,492.2		2,385.0
Other current assets		352.4		357.1
Total current assets		5,152.6		4,723.9
Property, plant and equipment, net		2,042.5		2,077.4
Goodwill		9,038.8		9,599.7
Intangible assets, net		6,850.6		7,257.6
Other assets		941.0		980.1
Total Assets	$	24,025.5	$	24,638.7
Liabilities and Stockholders' Equity
Current liabilities	$	1,816.2	$	1,941.5
Current portion of long-term debt		450.0		1,500.0
Other long-term liabilities		2,040.9		2,083.0
Long-term debt		7,840.2		6,721.4
Stockholders' equity		11,878.2		12,392.8
Total Liabilities and Stockholders' Equity	$	24,025.5	$	24,638.7

Page 11 of 25

ZIMMER BIOMET HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, unaudited)

	2020			2019
Cash flows provided by (used in) operating activities
Net (loss) earnings	$	(471.2	)	$	810.1
Depreciation and amortization		767.3			752.2
Share-based compensation		62.0			61.6
Goodwill and intangible asset impairment		645.0			70.1
Changes in operating assets and liabilities, net of acquired assets and liabilities
Income taxes		(55.0	)		(356.3	)
Receivables		13.6			109.5
Inventories		(108.6	)		(106.0	)
Accounts payable and accrued expenses		(131.4	)		(162.7	)
Other assets and liabilities		57.7			(16.0	)
Net cash provided by operating activities ⁽¹⁾		779.4			1,162.5
Cash flows provided by (used in) investing activities
Additions to instruments		(222.8	)		(239.5	)
Additions to other property, plant and equipment		(89.8	)		(155.3	)
Net investment hedge settlements		43.0			37.5
Acquisition of intellectual property rights		-			(197.6	)
Investments in other assets		(28.3	)		(36.4	)
Net cash used in investing activities		(297.9	)		(591.3	)
Cash flows provided by (used in) financing activities
Proceeds from senior notes		1,497.1			-
Redemption of senior notes		(1,500.0	)		-
Proceeds from term loans		-			200.0
Payments on term loans		-			(750.0	)
Net payments on other debt		-			(5.0	)
Dividends paid to stockholders		(148.7	)		(147.3	)
Proceeds from employee stock compensation plans		97.7			125.9
Net cash flows from unremitted collections from factoring programs		(39.6	)		(15.4	)
Business combination contingent consideration payments		(13.0	)		-
Debt issuance costs		(22.3	)		-
Other financing activities		(6.7	)		(5.4	)
Net cash used in financing activities		(135.5	)		(597.2	)
Effect of exchange rates on cash and cash equivalents		3.4			(4.3	)
Increase (decrease) in cash and cash equivalents		349.4			(30.3	)
Cash and cash equivalents, beginning of period		617.9			542.8
Cash and cash equivalents, end of period	$	967.3		$	512.5

⁽¹⁾ 2019 reflects approximately $168 million paid related to a patent litigation matter

Page 12 of 25

ZIMMER BIOMET HOLDINGS, INC.
NET SALES BY GEOGRAPHY
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, unaudited)

	Three Months Ended September 30,
	2020		2019		% Inc / (Dec)				Volume / Mix				Price				Foreign Exchange
Americas	$	1,216.5	$	1,179.2		3.2		%		6.7		%		(3.4	)	%		(0.1	)	%
EMEA		366.2		374.6		(2.3	)			(4.8	)			(0.9	)			3.4
Asia Pacific		346.6		338.6		2.3				2.1				(1.4	)			1.6
Total	$	1,929.3	$	1,892.4		2.0		%		3.7		%		(2.6	)	%		0.9		%

ZIMMER BIOMET HOLDINGS, INC.
NET SALES BY PRODUCT CATEGORY
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, unaudited)

	Three Months Ended September 30,
	2020		2019		% Inc / (Dec)				Volume / Mix				Price				Foreign Exchange
Knees	$	648.7	$	651.9		(0.5	)	%		1.4		%		(2.8	)	%		0.9	%
Hips		484.1		459.2		5.4				7.3				(2.9	)			1.0
S.E.T		359.9		348.5		3.3				4.9				(2.4	)			0.8
Dental, Spine & CMFT		295.5		275.5		7.3				9.0				(2.5	)			0.8
Other		141.1		157.3		(10.3	)			(10.1	)			(1.0	)			0.8
Total	$	1,929.3	$	1,892.4		2.0		%		3.7		%		(2.6	)	%		0.9	%

Page 13 of 25

ZIMMER BIOMET HOLDINGS, INC.
NET SALES BY GEOGRAPHY
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, unaudited)

	Nine Months Ended September 30,
	2020		2019		% (Dec)				Volume / Mix				Price				Foreign Exchange
Americas	$	3,051.5	$	3,587.6		(14.9	)	%		(11.9	)	%		(2.9	)	%		(0.1	)	%
EMEA		983.0		1,276.5		(23.0	)			(21.5	)			(1.2	)			(0.3	)
Asia Pacific		904.7		992.4		(8.8	)			(7.8	)			(1.2	)			0.2
Total	$	4,939.2	$	5,856.5		(15.7	)	%		(13.4	)	%		(2.2	)	%		(0.1	)	%

ZIMMER BIOMET HOLDINGS, INC.
NET SALES BY PRODUCT CATEGORY
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, unaudited)

	Nine Months Ended September 30,
	2020		2019		% (Dec)				Volume / Mix				Price				Foreign Exchange
Knees	$	1,652.7	$	2,049.5		(19.4	)	%		(16.7	)	%		(2.5	)	%		(0.2	)	%
Hips		1,246.4		1,421.1		(12.3	)			(9.5	)			(2.7	)			(0.1	)
S.E.T		946.1		1,062.3		(10.9	)			(8.5	)			(2.3	)			(0.1	)
Dental, Spine & CMFT		729.7		855.2		(14.7	)			(13.5	)			(1.2	)			-
Other		364.3		468.4		(22.2	)			(20.6	)			(1.6	)			-
Total	$	4,939.2	$	5,856.5		(15.7	)	%		(13.4	)	%		(2.2	)	%		(0.1	)	%

Page 14 of 25

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED NET SALES % CHANGE TO
CONSTANT CURRENCY % CHANGE
(unaudited)


	For the Three Months Ended
	September 30, 2020
					Foreign				Constant
					Exchange				Currency
	% Change				Impact				% Change
Geographic Results
Americas		3.2		%		(0.1	)	%		3.3		%
EMEA		(2.3	)			3.4				(5.7	)
Asia Pacific		2.3				1.6				0.7
Total		2.0		%		0.9		%		1.1		%
Product Categories
Knees
Americas		0.9		%		-		%		0.9		%
EMEA		(6.4	)			3.1				(9.5	)
Asia Pacific		1.7				1.8				(0.1	)
Total		(0.5	)			0.9				(1.4	)
Hips
Americas		7.9				(0.1	)			8.0
EMEA		0.8				3.4				(2.6	)
Asia Pacific		4.4				1.5				2.9
Total		5.4				1.0				4.4
S.E.T		3.3				0.8				2.5
Dental, Spine & CMFT		7.3				0.8				6.5
Other		(10.3	)			0.8				(11.1	)
Total		2.0		%		0.9		%		1.1		%

Page 15 of 25

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED NET SALES % CHANGE TO
CONSTANT CURRENCY % CHANGE
(unaudited)


	For the Nine Months Ended
	September 30, 2020
					Foreign				Constant
					Exchange				Currency
	% Change				Impact				% Change
Geographic Results
Americas		(14.9	)	%		(0.1	)	%		(14.8	)	%
EMEA		(23.0	)			(0.3	)			(22.7	)
Asia Pacific		(8.8	)			0.2				(9.0	)
Total		(15.7	)	%		(0.1	)	%		(15.6	)	%
Product Categories
Knees
Americas		(17.9	)	%		-		%		(17.9	)	%
EMEA		(27.4	)			(0.4	)			(27.0	)
Asia Pacific		(13.6	)			(0.2	)			(13.4	)
Total		(19.4	)			(0.2	)			(19.2	)
Hips
Americas		(10.3	)			(0.1	)			(10.2	)
EMEA		(20.6	)			(0.2	)			(20.4	)
Asia Pacific		(7.0	)			0.2				(7.2	)
Total		(12.3	)			(0.1	)			(12.2	)
S.E.T		(10.9	)			(0.1	)			(10.8	)
Dental, Spine & CMFT		(14.7	)			-				(14.7	)
Other		(22.2	)			-				(22.2	)
Total		(15.7	)	%		(0.1	)	%		(15.6	)	%

Page 16 of 25

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED TO ADJUSTED RESULTS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, except per share amounts, unaudited)


FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020
	Cost of products sold, excluding intangible asset amortization			Intangible asset amortization			Research and development			Selling, general and administrative			Restructuring and other cost reduction initiatives			Quality remediation			Acquisition, integration and related			Other income (expense), net			Provision (benefit) for income taxes			Net Earnings of Zimmer Biomet Holdings, Inc.			Diluted earnings per common share
As Reported	$	569.4		$	149.7		$	85.9		$	790.0		$	16.2		$	9.8		$	9.1		$	10.6		$	9.7		$	242.5		$	1.16
Inventory and manufacturing-related charges⁽¹⁾		(2.3	)		-			-			-			-			-			-			-			4.3			(2.0	)		(0.01	)
Intangible asset amortization⁽²⁾		-			(149.7	)		-			-			-			-			-			-			39.3			110.4			0.53
Restructuring and other cost reduction initiatives⁽⁴⁾		-			-			-			-			(16.2	)		-			-			-			6.5			9.7			0.05
Quality remediation⁽⁵⁾		(0.2	)		-			-			-			-			(9.8	)		-			-			3.2			6.8			0.03
Acquisition, integration and related⁽⁶⁾		-			-			-			-			-			-			(9.1	)		-			1.9			7.2			0.03
Litigation⁽⁷⁾		-			-			-			(19.3	)		-			-			-			-			6.8			12.5			0.06
European Union Medical Device Regulation⁽⁸⁾		-			-			(2.0	)		-			-			-			-			-			1.1			0.9			0.01
Other charges⁽⁹⁾		-			-			-			(0.3	)		-			-			-			(8.6	)		(4.7	)		(3.6	)		(0.02	)
Tax adjustments relating to the impacts of tax only amortization in Switzerland⁽¹⁰⁾		-			-			-			-			-			-			-			-			(1.9	)		1.9			0.01
Switzerland tax reform⁽¹¹⁾		-			-			-			-			-			-			-			-			6.5			(6.5	)		(0.03	)
Other certain tax adjustments⁽¹²⁾		-			-			-			-			-			-			-			-			3.0			(3.0	)		(0.01	)
As Adjusted	$	566.9		$	-		$	83.9		$	770.4		$	-		$	-		$	-		$	2.0		$	75.7		$	376.8		$	1.81

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2019
	Cost of products sold, excluding intangible asset amortization			Intangible asset amortization			Research and development			Selling, general and administrative			Restructuring and other cost reduction initiatives			Quality remediation			Acquisition, integration and related			Provision (benefit) for income taxes			Net Earnings attributable to noncontrolling interest		Net Earnings of Zimmer Biomet Holdings, Inc.			Diluted earnings per common share
As Reported	$	535.7		$	146.6		$	114.4		$	826.4		$	5.4		$	20.7		$	(2.6	)	$	(247.4	)	$	0.9	$	431.1		$	2.08
Inventory and manufacturing-related charges⁽¹⁾		(11.6	)		-			-			-			-			-			-			6.8			-		4.8			0.02
Intangible asset amortization⁽²⁾		-			(146.6	)		-			-			-			-			-			27.0			-		119.6			0.58
Restructuring and other cost reduction initiatives⁽⁴⁾		-			-			-			-			(5.4	)		-			-			1.3			-		4.1			0.02
Quality remediation⁽⁵⁾		(0.8	)		-			-			-			-			(20.7	)		-			4.8			-		16.7			0.08
Acquisition, integration and related⁽⁶⁾		-			-			-			-			-			-			2.6			(0.5	)		-		(2.1	)		(0.01	)
Litigation⁽⁷⁾		-			-			-			(42.8	)		-			-			-			8.7			-		34.1			0.16
European Union Medical Device Regulation⁽⁸⁾		-			-			(11.4	)		-			-			-			-			2.1			-		9.3			0.05
Other charges⁽⁹⁾		-			-			-			(18.5	)		-			-			-			4.6			0.1		13.8			0.07
Switzerland tax reform⁽¹¹⁾		-			-			-			-			-			-			-			263.8			-		(263.8	)		(1.27	)
Other certain tax adjustments⁽¹²⁾		-			-			-			-			-			-			-			1.2			-		(1.2	)		(0.01	)
As Adjusted	$	523.3		$	-		$	103.0		$	765.1		$	-		$	-		$	-		$	72.4		$	1.0	$	366.4		$	1.77

Page 17 of 25

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF REPORTED TO ADJUSTED RESULTS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, except per share amounts, unaudited)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020
	Cost of products sold, excluding intangible asset amortization			Intangible asset amortization			Research and development			Selling, general and administrative			Goodwill and intangible asset impairment			Restructuring and other cost reduction initiatives			Quality remediation			Acquisition, integration and related			Other income (expense), net			Provision (benefit) for income taxes			Net (Loss) Earnings of Zimmer Biomet Holdings, Inc.			Diluted (loss) earnings per common share
As Reported	$	1,481.0		$	445.0		$	272.0		$	2,283.9		$	645.0		$	89.2		$	35.9		$	15.7		$	17.4		$	1.2		$	(472.6	)	$	(2.29	)
Inventory and manufacturing-related charges⁽¹⁾		(4.3	)		-			-			-			-			-			-			-			-			10.2			(5.9	)		(0.03	)
Intangible asset amortization⁽²⁾		-			(445.0	)		-			-			-			-			-			-			-			77.5			367.5			1.78
Goodwill and intangible asset impairment⁽³⁾		-			-			-			-			(645.0	)		-			-			-			-			5.7			639.3			3.09
Restructuring and other cost reduction initiatives⁽⁴⁾		-			-			-			-			-			(89.2	)		-			-			-			18.7			70.5			0.34
Quality remediation⁽⁵⁾		0.1			-			-			-			-			-			(35.9	)		-			-			7.3			28.5			0.14
Acquisition, integration and related⁽⁶⁾		-			-			-			-			-			-			-			(15.7	)		-			2.9			12.8			0.06
Litigation⁽⁷⁾		-			-			-			(100.4	)		-			-			-			-			-			18.7			81.7			0.40
European Union Medical Device Regulation⁽⁸⁾		-			-			(19.1	)		-			-			-			-			-			-			3.2			15.9			0.07
Other charges⁽⁹⁾		-			-			-			(18.1	)		-			-			-			-			(12.5	)		7.9			(2.3	)		(0.01	)
Tax adjustments relating to the impacts of tax only amortization in Switzerland⁽¹⁰⁾		-			-			-			-			-			-			-			-			-			(18.1	)		18.1			0.09
Switzerland tax reform⁽¹¹⁾		-			-			-			-			-			-			-			-			-			6.5			(6.5	)		(0.03	)
Other certain tax adjustments⁽¹²⁾		-			-			-			-			-			-			-			-			-			6.1			(6.1	)		(0.03	)
Effect of dilutive shares assuming net earnings⁽¹³⁾		-			-						-			-			-			-						-			-			-			(0.02	)
As Adjusted	$	1,476.8		$	-		$	252.9		$	2,165.4		$	-		$	-		$	-		$	-		$	4.9		$	147.8		$	740.9		$	3.56

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019
	Cost of products sold, excluding intangible asset amortization			Intangible asset amortization			Research and development			Selling, general and administrative			Intangible asset impairment			Restructuring and other cost reduction initiatives			Quality remediation			Acquisition, integration and related			Provision (benefit) for income taxes			Net earnings (loss) attributable to noncontrolling interest			Net (Loss) Earnings of Zimmer Biomet Holdings, Inc.			Diluted (loss) earnings per common share
As Reported	$	1,670.4		$	436.9		$	328.2		$	2,461.6		$	70.1		$	17.0		$	63.1		$	8.5		$	(193.5	)	$	(0.8	)	$	810.9		$	3.93
Inventory and manufacturing-related charges⁽¹⁾		(47.7	)		-			-			-			-			-			-			-			19.8			-			27.9			0.14
Intangible asset amortization⁽²⁾		-			(436.9	)		-			-			-			-			-			-			85.0			-			351.9			1.71
Intangible asset impairment⁽³⁾		-			-			-			-			(70.1	)		-			-			-			5.5			-			64.6			0.31
Restructuring and other cost reduction initiatives⁽⁴⁾		-			-			-			-			-			(17.0	)		-			-			4.0			-			13.0			0.06
Quality remediation⁽⁵⁾		(1.5	)		-						-			-			-			(63.1	)		-			14.9			-			49.7			0.24
Acquisition, integration and related⁽⁶⁾		-			-			-			-			-			-			-			(8.5	)		2.5			-			6.0			0.03
Litigation⁽⁷⁾		-			-			-			(48.0	)		-			-			-			-			7.9			-			40.1			0.19
Litigation settlement gain⁽¹⁴⁾		-			-			-			23.5			-			-			-			-			(5.2	)		-			(18.3	)		(0.09	)
European Union Medical Device Regulation⁽⁸⁾		-			-			(18.1	)		-			-			-			-			-			3.2			-			14.9			0.07
Other charges⁽⁹⁾		-			-			(4.3	)		(78.8	)		-			-			-			-			17.8			1.3			64.0			0.31
Switzerland tax reform⁽¹¹⁾		-			-			-			-			-			-			-			-			263.8			-			(263.8	)		(1.27	)
Other certain tax adjustments⁽¹²⁾		-			-			-			-			-			-			-			-			12.6			-			(12.6	)		(0.06	)
As Adjusted	$	1,621.2		$	-		$	305.8		$	2,358.3		$	-		$	-		$	-		$	-		$	238.3		$	0.5		$	1,148.3		$	5.57

Page 18 of 25

⁽¹⁾

Inventory and manufacturing-related charges include excess and obsolete inventory charges on certain product lines we intend to discontinue and other inventory and manufacturing-related charges. In the nine-month period ended September 30, 2019, inventory and manufacturing-related charges also included a $20.8 million charge incurred to terminate a raw material supply agreement.

⁽²⁾

We exclude intangible asset amortization from our non-GAAP financial measures because we internally assess our performance against our peers without this amortization. Due to various levels of acquisitions among our peers, intangible asset amortization can vary significantly from company to company.

⁽³⁾

In the first quarter of 2020, we recognized goodwill impairment charges of $470.0 million and $142.0 million related to our EMEA and Dental reporting units, respectively. In the second quarters of 2020 and 2019, we recognized $33.0 million and $70.1 million, respectively, of in-process research and development (“IPR&D”) intangible asset impairments on certain IPR&D projects.

⁽⁴⁾

In December 2019, our Board of Directors approved, and we initiated, a new global restructuring program that includes a reorganization of key businesses and an overall effort to reduce costs in order to accelerate decision-making and focus the organization on priorities to drive growth. Restructuring and other cost reduction initiatives also include other cost reduction initiatives that have the goal of reducing costs across the organization.

⁽⁵⁾

We are addressing inspectional observations on Form 483 and a Warning Letter issued by the U.S. Food and Drug Administration (“FDA”) following its previous inspections of our Warsaw North Campus facility, among other matters. This quality remediation has required us to devote significant financial resources and is for a discrete period of time. The majority of the expenses are related to consultants who are helping us to update previous documents and redesign certain processes.

⁽⁶⁾	The acquisition, integration and related gains and expenses we have excluded from our non-GAAP financial measures resulted from various acquisitions.

⁽⁷⁾

We are involved in routine patent litigation, product liability litigation, commercial litigation and other various litigation matters. We review litigation matters from both a qualitative and quantitative perspective to determine if excluding the losses or gains will provide our investors with useful incremental information. Litigation matters can vary in their characteristics, frequency and significance to our operating results. The litigation charges and gains excluded from our non-GAAP financial measures in the periods presented relate to product liability matters where we have received numerous claims on specific products, patent litigation and commercial litigation related to a common matter in multiple jurisdictions. In regards to the product liability matters, due to the complexities involved and claims filed in multiple districts, the expenses associated with these matters are significant to our operating results. Once the litigation matter has been excluded from our non-GAAP financial measures in a particular period, any additional expenses or gains from changes in estimates are also excluded, even if they are not significant, to ensure consistency in our non-GAAP financial measures from period-to-period.

⁽⁸⁾

The European Union Medical Device Regulation imposes significant additional premarket and postmarket requirements. The new regulations provide a transition period until May 2021 for currently-approved medical devices to meet the additional requirements. For certain devices, this transition period can be extended until May 2024. We are excluding from our non-GAAP financial measures the incremental costs incurred to establish initial compliance with the regulations related to our currently-approved medical devices. The incremental costs primarily include third-party consulting necessary to supplement our internal resources.

⁽⁹⁾

We have incurred other various expenses from specific events or projects that we consider highly variable or that have a significant impact to our operating results that we have excluded from our non-GAAP measures. These include costs related to legal entity, distribution and manufacturing optimization, including contract terminations, gains and losses from changes in fair value on our equity investments, as well as our costs of complying with our Deferred Prosecution Agreement (“DPA”) with the U.S. government related to certain Foreign Corrupt Practices Act matters involving Biomet and certain of its subsidiaries. Under the DPA, we were subject to oversight by an independent compliance monitor, which monitorship concluded in August 2020. We expect the one-count criminal information filed against us in 2017 to be dismissed with prejudice in February 2021 and the DPA to conclude at that time. The excluded costs include the fees paid to the independent compliance monitor and to external legal counsel assisting in the matter.

⁽¹⁰⁾	Represents tax adjustments relating to the impacts of tax only amortization resulting from Swiss Tax Reform as well as certain restructuring transactions in Switzerland.

⁽¹¹⁾	Switzerland passed the Federal Act on Tax Reform and AHV Financing (TRAF), effective January 1, 2020. Certain provisions of the TRAF were enacted in the third quarter of 2019, resulting in provisional adjustments to our deferred taxes, generating a net tax benefit.

⁽¹²⁾	Other certain tax adjustments relate to various discrete tax period adjustments.

⁽¹³⁾	Diluted share count used in Adjusted Diluted EPS:

Page 19 of 25

	Nine Months Ended
	September 30, 2020

Diluted shares		206.8
Dilutive shares assuming net earnings		1.4
Adjusted diluted shares		208.2

⁽¹⁴⁾	In the first quarter of 2019, we settled a patent infringement lawsuit out of court, and the other party agreed to pay us an upfront, lump-sum amount for a non-exclusive license to the patent.

Page 20 of 25

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF NET CASH PROVIDED BY OPERATING
ACTIVITIES TO FREE CASH FLOW
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Net cash provided by operating activities	$	381.3		$	577.9		$	779.4		$	1,162.5
Additions to instruments		(63.5	)		(94.7	)		(222.8	)		(239.5	)
Additions to other property, plant and equipment		(30.6	)		(58.6	)		(89.8	)		(155.3	)
Free cash flow	$	287.2		$	424.6		$	466.8		$	767.7

Page 21 of 25

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF GROSS PROFIT & MARGIN TO ADJUSTED GROSS
PROFIT & MARGIN
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020				2019
Net Sales	$	1,929.3		$	1,892.4		$	4,939.2			$	5,856.5
Cost of products sold, excluding intangible asset amortization		569.4			535.7			1,481.0				1,670.4
Intangible asset amortization		149.7			146.6			445.0				436.9
Gross Profit	$	1,210.2		$	1,210.1		$	3,013.2			$	3,749.2

Inventory and manufacturing-related charges		2.3			11.6			4.3				47.7
Quality remediation		0.2			0.8			(0.1	)			1.5
Intangible asset amortization		149.7			146.6			445.0				436.9
Adjusted gross profit	$	1,362.4		$	1,369.1		$	3,462.4			$	4,235.3


Gross margin		62.7	%		63.9	%		61.0		%		64.0	%
Inventory and manufacturing-related charges		0.1			0.6			0.1				0.8
Quality remediation		-			-			-				-
Intangible asset amortization		7.8			7.9			9.0				7.5
Adjusted gross margin		70.6	%		72.4	%		70.1		%		72.3	%

Page 22 of 25

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF OPERATING PROFIT (LOSS) & MARGIN TO ADJUSTED OPERATING PROFIT & MARGIN
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(in millions, unaudited)


	Three Months Ended September 30,							Nine Months Ended September 30,
	2020			2019				2020				2019
Operating profit (loss)	$	299.2		$	245.8			$	(328.5	)		$	800.7
Inventory and manufacturing-related charges		2.3			11.6				4.3				47.7
Intangible asset amortization		149.7			146.6				445.0				436.9
Goodwill and intangible asset impairment		-			-				645.0				70.1
Restructuring and other cost reduction initiatives		16.2			5.4				89.2				17.0
Quality remediation		10.0			21.5				35.8				64.6
Acquisition, integration and related		9.1			(2.6	)			15.7				8.5
Litigation		19.3			42.8				100.4				48.0
Litigation settlement gain		-			-				-				(23.5	)
European Union Medical Device Regulation		2.0			11.4				19.1				18.1
Other charges		0.3			18.5				18.1				83.1
Adjusted operating profit	$	508.1		$	501.0			$	1,044.1			$	1,571.2


Operating profit (loss) margin		15.5	%		13.0		%		(6.7	)	%		13.7		%
Inventory and manufacturing-related charges		0.1			0.6				0.1				0.8
Intangible asset amortization		7.8			7.9				9.0				7.5
Goodwill and intangible asset impairment		-			-				13.1				1.2
Restructuring and other cost reduction initiatives		0.8			0.3				1.8				0.3
Quality remediation		0.5			1.1				0.7				1.1
Acquisition, integration and related		0.5			(0.1	)			0.3				0.1
Litigation		1.0			2.3				2.0				0.8
Litigation settlement gain		-			-				-				(0.4	)
European Union Medical Device Regulation		0.1			0.6				0.4				0.3
Other charges		-			0.8				0.4				1.4
Adjusted operating profit margin		26.3	%		26.5		%		21.1		%		26.8		%

Page 23 of 25

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF EFFECTIVE TAX RATE TO ADJUSTED EFFECTIVE TAX RATE
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 and 2019
(unaudited)


	Three Months Ended September 30,								Nine Months Ended September 30,
	2020				2019				2020				2019
Effective tax rate		3.8		%		(134.1	)	%		(0.3	)	%		(31.4	)	%
Tax effect of adjustments made to earnings before taxes⁽¹⁾		9.8				7.2				15.8				3.8
Tax adjustments relating to the impacts of tax only amortization in Switzerland		(0.7	)			-				3.8				-
Switzerland tax reform		2.5				142.8				(1.4	)			42.8
Other certain tax adjustments		1.2				0.6				(1.3	)			2.0
Adjusted effective tax rate		16.6		%		16.5		%		16.6		%		17.2		%

⁽¹⁾ Includes inventory and manufacturing-related charges; intangible asset amortization; goodwill and intangible asset impairment; restructuring and other cost reduction initiatives; quality remediation; acquisition, integration and related; litigation; litigation settlement gain; European Union Medical Device Regulation; and other charges

Page 24 of 25

ZIMMER BIOMET HOLDINGS, INC.
RECONCILIATION OF DEBT TO NET DEBT
AS OF SEPTEMBER 30, 2020 and DECEMBER 31, 2019
(in millions, unaudited)


	September 30, 2020			December 31, 2019
Debt, both current and long-term	$	8,290.2		$	8,221.4
Cash and cash equivalents		(967.3	)		(617.9	)
Net debt	$	7,322.9		$	7,603.5

Page 25 of 25

Document and Entity Information	Nov. 06, 2020
Document And Entity Information [Line Items]
Amendment Flag	false
Entity Central Index Key	0001136869
Document Type	8-K
Document Period End Date	Nov. 06, 2020
Entity Registrant Name	ZIMMER BIOMET HOLDINGS, INC.
Entity Incorporation State Country Code	DE
Entity File Number	001-16407
Entity Tax Identification Number	13-4151777
Entity Address, Address Line One	345 East Main Street
Entity Address, City or Town	Warsaw
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46580
City Area Code	(574)
Local Phone Number	267-6131
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	Common Stock, $0.01 par value
Trading Symbol	ZBH
Security Exchange Name	NYSE
One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]
Document And Entity Information [Line Items]
Security 12b Title	1.414% Notes due 2022
Trading Symbol	ZBH 22A
Security Exchange Name	NYSE
Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]
Document And Entity Information [Line Items]
Security 12b Title	2.425% Notes due 2026
Trading Symbol	ZBH 26
Security Exchange Name	NYSE
One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]
Document And Entity Information [Line Items]
Security 12b Title	1.164% Notes due 2027
Trading Symbol	ZBH 27
Security Exchange Name	NYSE

GRAPHIC 3 ggzpdjehyjgu000001.jpg GRAPHIC begin 644 ggzpdjehyjgu000001.jpg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
-*I\-J8QOU^81ECY M)6J+*:PSIBHOVFNF#]$#*TFG+]#IIJIIG].3D4A[WRH&3(?W4I /YN=Y^\N? MW#U&6E:5*=G9UB?V<.,7D2B^%ZZN=/&W;?""HVNMNGL1Z=/3OI?:72(:YKD+ M>1W"R;?VMSA*.+&2XX]A\DTN%ZZN-R58Q?EI)RRYP0=H1@%6[SX\N_I.;JG# MRFR?5E7S1VP=Q&:+>Q:;=MO6HM0=]ABF (V+JQB57*"=+UU?RI+RHM<4H75RD>:_K@[J?>[[$Y!I,9:,!REVNX75+$RBE2:$[RB9$;8LJI,*B0W:NT58]P ='V>>/J5W M[_:3=JVQ@3KI.DMQE1\)Y4O]*_?Y22M*O&,E=IPD>MOHV[6?V.V%+>NJ6^G7 MM>49PJOBMX4:NQ'CR\]MWW1TE"5FJK FYSK8=QB*GR\<0T.3_%RBP=;8 MT@'/UYR[!;_GL MK>]K#RY].A:FXV+R;^&,VZ6;OL71-],F^"MSFWR1UE]5/:J'S\"UU;G MT:,\K':7Q3MI5R;"\7YEN/7&*XRNVK:7!NNKW@;Y6+[(TU:.,]LDAK^* M6'=DZQ7B_N]Y]->2A>M02I$GWSJN=XA@# & 4N;S\1US1K-UN%;8ZEXOK,J] M:;!!LUG=3VN=TJUB99VP;J.3H[C01.X.BW 3B0A"B81Z% /9FWH1*GEOUE;F MW_5#Q7_DCMO^^C'0O>*C]96YM_U0\5_Y([;_ +Z,="]XJ/UE;FW_ %0\5_Y( M[;_OHQT+WBIL?Q)\XOD/Y;+ZS^[6!LC-2*51VV1"LT]B8'MMM+ M]R;<+E)JT@H)%98!,F?U5@31(0ZJA$S1PBE4%N#-92M5Y2O,OR5X/#V];7R:XG:/WS>(RO0]LV93_K!.1E4;23.NLWGTM)L/2BFTO*3BSIM-@@V:SN MI[7.Z5:Q,L[8-U')T=QH(G<'1;@)Q(0A1,(]"@'LS;T(E2?+Q+^0N8\@^CKA M:[[#T^L;:UQ>%*W<:Y2$)=G C!3#(DK2[&Q8SLW8Y1HA+(I/69P5>*][J,7. M4"$,4H82C1^XI*IF(& , A&\P'E/N?CY-IRH:=KFN[ALS8I;!9)Z/V(RL4G% M0%$AQ0C(]X1E6;14WY9"Q6!PL1LJ9PHB"<:Y*9/N,0Q78)3B,.*QFHK-7"7K@7O3.7J M4<^A$J7-8R2CYF-CYB)>-I&*EF+22C)!FJ1=H_CWR";IF\:KIB9-9LZ;*E.0 MY1$#%, AFHI][ & ?X553134664(DBD0ZJJJIRIIIIIE$QU%#F$"D(0H"(B( M@ & 4V=O_$C\E(G:NQHK3^L..\MJN*NEDC->3%JKFRGUCFJ?'RSIG 34RYB M=IPD:9],1R*;DY46J*:?J]@ /;W#M4%3B2I.)XA^>>V?(!I39>R=O5G7=7FZ M9M(]'C&FMXRRQ<4XBBU.N3P.7R-GM5M=J2'O-5H&'E#*2KF'V MG!QBS@'$@*EACQ%\ZMK<_ M= [ VMMVM:]J\_4]P2FO8]CKB-L<9#KP[*ETFQI.GB%FM-L>GDC/;*N0QR+I MI>D0@ F!@,8V$E1T13>GDQLN;TOQOY [BK+.*D+)J?2.UMEU]A.HNW$(^FZ) M1)ZT1+.9;Q[V-?KQ3E_%)D<$04 MX"X:U1WL"F/%4^H=Q47\Q9;X@@<0Z]#&;* _8'Y,="%28SAMYU^)7*6?AM? M71O,<==GSJZ#&(A[_)1\G19Z5='*FVB('8[-*/:!(N%3=B2%#$30%5 M4Y4\Q<&BDV68 8 P!@&L/-'=EGXX\5=Z;SI<= R]JUA092U04;:&\@[K[Q^R M.@5)"6;1,G#22S,P*CW%1=(''[!@RI5= 5+OUE;FW_5#Q7_DCMO^^C-G0O>2 MH_65N;?]4/%?^2.V_P"^C'0O>*GM*E\3)R89/$3WOCQHNR1Y3E%=K4G]_I3Q M1/K\XJ+Z9L-_00.(?(8S90 _8''0A4FXX+^:7BYS3L,9K1RWF-'[IE^B4/0K MT^8OH:V/>SO/'T>\,B,V$W)%^0C-XUC'[D>ONZ"P%,)<'%KCX%)@\Q P"GON MGXA#F#KCD-MG4D+JOC6[KM#W/>]\2M98.Y%=IMQDQ5E%F M+$AUCI-TDC*B(E3*7H4-G0J5(7",UE& ?3D9&/AX]]+2S]G%Q48S77Q#?&W3,G*TSCM M57W)&V1RJ[)Q:T)8*GJ5H[3$4C&CK$=C)S5R*V6*/4S)FBPDMA,@.3WAC8M=NXDRB(#T4*@ZIEDK! MT%C%_:G,54I3=!$A@^:+H0)D.)'Q$/'7<$I%TSDA3G_'.SR*B#-OJ5IGV::"KN#KLW,-4G)5#-U'$;&.7J";@J2B*ID#JH@!P*>7%F"W).Q]=@MBQED ML=(V;6ZJ1^A P]GAG*;Y@:);2\G+RJ,?+U*5CGA07<+"15=1,#G]/KF$E1E) M"8+8W!#;>NM-:+JFK;E:9*E.KML=38\=:IAO"-)>3&.I<9%I MU2XU$S.2<)0\@Y=E$3KR*:WJLU>Y YP+V'$IR MV4$E4A:-S64AJ\POD4W+X]JEHZ>T]4]96IWLVQ76(G$ME15JE&S-M6XVOO62 MD42KW"HJHKK*RR@*BL=7CGGMGQ_P"E-:;)U#6==VB;N>TB4>3: M;(C++*13>*-4['/"Y8HUBU5)VG(>]PZ9>Y191/TS&#L[A P2*3YE*^OZRMS; M_JAXK_R1VW_?1F?0O>2H_65N;?\ 5#Q7_DCMO^^C'0O>*C]96YM_U0\5_P"2 M.V_[Z,="]XJ/UE;FW_5#Q7_DCMO^^C'0O>*DFOB?\PG([G?R;F=+;8H6DJS6 M([4UIOB,CKR!O<9.FEH.P4Z):ME7%DV):H\8Y1O85C*%!L543D((*% # ;&4 M4E5 L=9@4\U<[5$T2GVN[SZWN\%3:U.VJ:7ZE#T(FO1;J7D5NIA*4/39LSF] MH@'LS^S3L&_JFH6-,Q57*R+T+4%[97)*$5^%H_/U?4\71=)RM9SGTX6)CW+U MQ^R%J$IS?U1BRIMX9:9+[U$ZC8V;VLP-E:8^F&3*UCI?'R]](VD97<3OAJG0==O5?_ /;_ +@_ MDX?_ (AB$4'@[M:Y:4K=B,NC-C[ON!B*1=$KSB0:1HK%06L%@=-VI3=!!(%14-\PAA#Z?9NU\[>>YL/;6G\+^5=47*E5"VOBN7'[H04I4\: M47%H^+[A[VTSMULO4-Y:M1XV%8[)+6FPOS=Q2K2N"MTC&.#9DW,KZ:")1[$4"$3+T M*4 SUHT?2<'0=*Q]%TR'EX&+9C:MQ]D8))5?BW2LGS;;;XL\&-PZ]J>Z-=R] MQZS<=W5NR]L[DG)T7A%5I&*X1BE%<$CQ.?I'XXP!@# -V_'OQ5>\O\ MD_1-7KMG)J/'+_7/:;]#U4P8Z_KSEJI*M?>4A [5U9':[>*;*%ZF37?%4Z"4 MANG&W=C?-OM_LK*UJ+7Z3FO)QHNGQ7[B?2Z/FK:4KLEXQ@US:.8NQ';*]W6[ MD86VYQE^AK;^\9DE5=.+::N2O7I.5V< MG*4FZMMNK;;XMM\6_$]S+-FSC688^/&,+%N*C&,4E&,8JD8I+@DDDDEP2/M9 M@;3^" & 0$ $! 0$!#J @/L$! ?8("&!SX/D4XHIJ/C>\R+>*9=T+JZQ;%;Q MJ*1 ]VBON0;V*C[H@(!VBI%:_E9=/_A%>!Z_.Z>WT*OS_P 8/3T[]S[36[.& MY-\Y?>\*M7_*OQ@_YM_P/)C&M_L^^K2.+9^QVWD:@H)KZ%7YUK*K-0A()F_:%:,W19.8*DI\]15F@)@%)TD.R"?-D)9?!+P"_PRZ$'D'L:%]UW; MR$AX^0:-GS?TY*C:C5,C)5FNB14OK,I.VJ%2F)(G4INSW%!0A%6I^N,W5T\" MD\^8 HL/WF;S=#Y2%K#Q)?HX.)7WLO\ S'/9KG\Q21?,0!BE,)#OWRA$2CT'H8X" M.?T-TXD)*/!1R=/QWYT5NCS[X\?2>1+$VGYYNY.*+9KFG,K"(=3?\ ABX';8E(J0]QO&V$$])T,4U?2=$DKZT?-[') M-5"#Z[=>$HC25=(+%#]S=IH!U*)BCF455@Y^CC7MF::XB-JN60HT^?NM@H,, M_-W_ .OV.J0=;L%B:HAV]G;%QMPC#''KU$790Z>P.:THX=.W3A0RBBBAC'4.83&$1$1 MS2VZLIF3_!MQ"_)5XW?V&ZQ^U?%6!_@VXA?DJ\;O[#=8_:OBK!EBA:QUKJJ* M=P6K]>4;6\(_D#RSZ'H53@*?%/)55LV9J2;N/KT?'-'$@HT9HI&6.05!32(4 M1[2E (# W/?\1?FC^:;R,_ _<_)5QNJEXK%>N57E?NP_2 ME;M<+&V* DO<=";2DF7O\/+MGD<\]SD6:+A+U$S>FLD0Y>ABE$-LOE(7QO\ M"+Q0_)BX\_V+:W^UK-564\'=_'SP:V)&.(JU<2>/KE%TFHD=Y$ZLJ-6G$R*A MT/[I9*K&0MA8''Y>Y!TF8! ! >H .*OV@I[>9;Q=5K@E9Z9L[2SJ8N+LR:&E25KZ;XKSFN]D3+JQ;&XX3<-3EI^0<'=RTYKNQ1[QWKU]-.U3"L[E6 M PDG%F5. G6;QJ*BAU%CJG'&:HRDY>8 8 P"/_RI?H[>7GWF[!^_,\RC\R!4 M4\"=-J%ZY^Q<#=ZK6[C!FU'LEV:&M4'&6&),Z;)0PMW)HZ7:O&8N$!./8?L[ MB]1Z"'7-D^"(7>_\,G&W\GS1_P#9/0O_ . 9JJ_:RF)MH^/3@_N.%>P=ZXLZ M3 H,#2[6U*J!NIHZX4UG VB.4*8W< HNR?.#J(#CJ:!1@\FW"]S MX\^6:M I-CG75+EHB$VKIVSN'8M[1&0CN6D6:#%]*1Q&92V*I66 0\<_(>5Y4\*N/^[K$L1Q;++3U8BZ.2E(D+VY4>:E:+ M9Y4[=,"D:C.3%<5?%3* %(1R4"_-Z9J:HZ%-V,@.8ORI_'9Y'_G3;@_"U8LW M^!#IT9H*!$ 1$>@![1$?8 'RB(X!1L\RWE6LO*'8-@XUZ(LCMAQOI,PK"S MDC .U"'WC:XMT*#J2>.FA@%[KZ+D$A)$LBB=N_43!^KZ@F:$:[8QIQ?,AN]X MV? 15GE6KFZ^=#"4D):=:M)JM\>FSY]!-(2.7*1RQ<;4DXU9I-+SCE,2J#"M M5FR;(O0CQ190ZK5"2GX(%EG7&@=&Z?C&\-JK3VLM=1K5,J23:F4:MUT# 4"A MZCA6+C6RSMPH)0,HJJ8ZJA_G',)A$HV5E(YRNS<)B;N352,15,_0Q#%, #BK7(%93R7^ ZN0E4LF M\^#4?+-G$ U=S=KX\N'KZ?+(Q;5*R<5]B0''?=UF=R'&>]S"41%O)MX=4ND;5+.P3:ST:Y MB 0$ $! 0$ $! >H" ^T! 0 M]@@(9J*>(V=_1ML+^(]L_@%_E7,'+EUMKBT;7M!J=3F8R,_]5[];$&!0.9=X MPUU0[+L.<;,TDRG4<2"T%5G)6Z10$RRXD('M,&;R$[_PZW*#[E_*2V<=I^1] M"KJ((MOIVI+2SI,O.1#9Z82F( MV6B]<4Q!O[0(5=^)2@ '5 ,WK@J$-E?!A^E#XV_[+NC\ FS\D_E!T(-$K;D6#)[8HB1DF8I.\PFZ=1$<3YA%A'_!MQ"_)5XW?V M&ZQ^U?,*LH_P;<0OR5>-W]ANL?M7Q5@]13N-O'77=@9VS7^@]+46TQY'23"R MT[5E&K%@8IOFRK)ZFSF82"8R+8CQFN=%4"*%!1(YBFZE$0R5!ZZ_:MUEM:-9 MPVT==439,1'/@DX^*OU1K]QC6$D""S4)!FQL4?(M6KX&KA1/U2%*IZ9S%Z]# M" @8I_P;<0OR5>-W]ANL?M7RU8(9?/!QVX_:SX$R5GUQHO3NO[(3;>N&)+#2 M=94JJ3A63M29!VS++04(P?E:N03+ZB8*=A^T.H#T#,HL](ZAUW85F"\6K/4 M76M,J,RK&.56Z[F.4E("%CWQV#A=HDQ-5MVK\K[]SL6YWHO\N$5]+1P+ZG-I07&#:NQE4 3D-@[A6ATUNP ,X@*)6(8D<<5/E,5.:LTH4 M"_(40$?LCG)?JNU:65O7!TB+K:Q-/4Z>R=^Y/J_S+=M_^HX;]"F@QPNW&I[@ ME&E_/U9VT_;:QK-OHX^ZY>O+_P!9/=G5H[O$A6BC^8GG>G MH:)8H]!5>24IO;6+%@T2 1 /4<.ER$+_ ,(YR_V&R+.'W6TO+R9*./:CESE) M\E&.%DRDW]"39U_]4>)D:AV+UO PXN>7?E@VX17.4YZEAQC%>]R:1MSQZT[! M\?M(:MTQ7BH_1VNJ9"UP[E!/TRR'L79NF[0P$ON^G MX=NU5*G7-*MVX_?=N.=R7\:3,QY\\?6C *F/GEY=_7G95_TN[!_1FC7M]Z MC"F;G)VL>JXQQXR^.:]GG7(T7\2VFG29Y>>MKNI^FMPX_;#2;E=-TQJ]E]+X M3RYQ^SMNG!^1:E5_[2]*,EU6RO5G;(Z'C & , 8!=:\+W$;_ \\9&^S;5&> MZ[.Y!DC+E(@Y1['L)K]%%4] @! X=Z!WC%ZK+."_,-WR!$E2]S8O3SA]1>_O M[6[T>BX,^K1=)ZK,:/X9WVUY\_?225J/-4MN472;/8+TA]K/[!]N8[CU.WT[ MCUU0OSJOBMXJ3^[6O:NJ,G?ER=;L8R5;:)B-A4N7K%_$N27!KR9QO6>/M? MG7_HZ2Q'QFV2?<7'?1VTUU@6>W[5-#M$J8! PDFY6MQSF=;G,'L%1K,&72-T M]G<0W;J>AQ5+>+G7[ZBO[9JS6ME#9NX)NP 9V&R]ASDFYF82F/G"Q13D#V*9(K(S!>T MQ!CFZB)_3,[0,.V3HJ>)"^Z 4 *4 *4H !2@ = #V !FDI_< HL/WF;S=#Y2%K#Q)?HX.)7WLO\ S'/9KG\Q21?,0G5?PLI9OE\K(91\O_'&2X?>0"\R%-(YKU9V-*,>0&K)&-[FOT0O8Y9R_FFD M8HB ),5:OL..D"-44Q S=F#4W0H'+DBZQ!>(X6\BHSE?Q;TMOQ@=L#N^TM@X MM#-IT!&*O,096!O40F0/G$0CK;&/$D>X"B= "'Z !@S4U1T*;0Y 1U^5?DW_ M (4N#FZ-@QLA]'W:S0_W+-;*)J^B\+=M@I.8=O(QQ^H #ZKP7O\ -$ >H#]& MB'0?D'**JP5E/!-Q@^N*W*OE58([U(73NE+]0*$Y72'TU-A7RDS/U@D&*W00 M]YK=%(HV6*/3YD^F(=>GLSF_ A')XN_TAG$#[^%/_P"E'S)\F#I-9H*5ZOB4 M_P 1?5'YV5%_ _O;,X*;GMK".CPD+S$;-KNQ]7E(F"KO[H% M$HA9:+CV " E(ZM,;[Y"=P_M4Y,X^SY0RDZ21#$'@(Y/CHGFPTU;.R'N=)Y+ M0OW.GB:ZOI-$-@Q)W,SK605+U 5'CI^9["-R]!ZJS8=?DZ@FJJH+XV:BC *2 M_P 17R64VCRFI/&ZN/#O*_H"LIKSK1H8RA76T-E(1LP];F30$Q'BD14$(=)' MKW*(.'3M( *(F =L%PJ1GXOEDXRI<1^!OC+TRY9$:6Q@CNNS[&$"AZRVQKE' MZML5M175#VN0A'[[Z,04$ $6C%$.@=.@(NLF"4#X9_\ %1WU^<*K^#>CY)\P MBR%FLISD?+S^DDY9??#8_P SJSF^/RHA?^XR?BV\?/O'ZG_F% 9I?-_24SAD M P!@&IO/?\1?FC^:;R,_ _<83-D_E(7Q\TE& 4H/B4KG"3/+K3U.CG3=U*TK1#-:P%0,0ZD>[M%S MM#YA&O#%$3)N@BV23H$S '1%VF#:I3%2\:&@PFD%FJ]D=[*M MK)JN!BJ)0\WLJU'AEP*( (R<:@F\2$!$#)."F^ST#"?S%);\Q!S%^5/X[/( M_P#.FW!^%JQ9O\"'3HS04BE\S_)V0XP<#]D2=:D5(N][;>,-)TM\W5.B\CW- MU:22]HE&BB(E<-G^2,':*;)^U>S*?4>TRT,0ABF(/V1"L M$R]"D14EU&\OV% $T0F023 I$RE#=!U1"T/X7>34CR;X&:VD;+(J2EYU$]D- M(W%\X5.J[?KTEI&+U:2=J+"9PX=O:%,10N7!S',X>%7.)A,)@#7)492279W] M&VPOXCVS^ 7^1;N$DUT%Y+:"*Z"Q"JHK(JZ1V611)5,X& M(HFH0P@8H@(" ]!S;+Y2'D.9&I[9XY/(?:H^A K#!JW:<#N#2;TP*^['J#R4 M:W:C-Q.!B&?M8A/_ +'>_(199DX((=HB&5/J0.A%I#;58WSI_6>YZ:KZM9V= M2:[=(D@J%569HST:W?*Q;PQ *!9&(.0;U/3->*DKVNDJ_-M5WNQI'TRB50684IFYCC*%$/2 M<2B ^WKT'**JP0'^+OC![OX^?)IR\L,?T5D>-&Z=)ZU772Z&!DTU\^L^QI5L M"H#WI.G@P[)%=/IVF;/$NX>IRAG)\4B&KG@P_2A\;?\ 9=T?@$V?EG\H.A#F MDI5O^)U_HWXD?QWVO_ -+S9;\2,R'\,Y^+!R"^_TW_![5L3YA%DW-91@# & M, @W^(7_ $=LI]^76'[Y.9G#F&13_#)_TZ"N93Y$1<@S448 P"% M7SU3:L5P;D03_(A$E&SA([)F--LTA#8-4CJ\ MY1!PBVV+IVWJ(F+WD.&O-NT?8 >H0>H'3*:L )@'J E >OLS]G0=2EI.=/+@ MZ2EAY=JO_;XMZQ^'[3@?.[HT:&NZ9;P+BZH1U# OM?\ *YV/EICJPJ<$4I#%7.@YE%2 MJNQ3ZG18(KK=.B8Y]IV^V=E[[W;A[;QNI6[URMV:_P!79A\5V?LJHIJ->#FX MQ\3CGNQW!P>U^PM0WCF],KN/:Z;%MO\ TN3<^&Q;]K3FTYTXQMQG/E%G/7ME MJL%YM%CNELE',W:+;.2MDL4P\,!W2E'[@P 4HJNWKDYS= $WL M]F>L6!@XFF85G3L"$;6%8M1MVX+E&$(J,8KW))(\(-4U/.UK4LC5]4N2O:EE M7IW;MR7S3N7).*NS3K<^BU!2N5Y=2C%_,CG7T[=KI=U>Y>)I.7!RV[A_\5FOP=FW M)4M-^V_<<;5*]71*WD8QA%0@DH)427!)+DDO!(^3(9# & M 0=^?FM)2_#"HSOIA[U4]\5!Z58"@)BLI6IWN%=("8?:5-9T\;&']DR1<[+> ME?,EC]QHZB&VP*ZM[>O8E![0NC&.3_9^9$)M__P!& M?'>H#$CA]V]6C!4AW4=OG[Y MVX.F@U9LVJ)U%5#F*0A"B81 P#GT>0OE5L/RE4J_NRBZ)&K%-3J=O&- M6R(B84^X=3=74IMWD P"AQ\0M^D2E?O-ZP_>9O-T/E(6L/$E^C@XE?>R_P#, M<]FN?S%)%\Q!SA>'OZ5#0OYZ=5_"REF^7RLA:!^(5XM_=BXC16]J_'>\W+C5 M8!FGYT$N]TZUA=%8^#N+<"I@"BH1$NC%28F,(D;M&CLW0.\PYK@Z.A337X:O ME!W);HXA6&1^)$6P\UE*9?Q(O)OZY;QU?Q9@)#U(;3E>&^7EL@KU34V#?VR(P3!\CU'_6:[ M1D47*!O9\R>4 >OV-L%PJ1D\?"?C#_A*\8#/6,C'_1]VEM+7W8^S"*)>D\"_ M7VI/YJ4CY H&=U:..TA>X ^ 9E%U0+U_$[?L)RCXWZS*SI?5VP]N7-Q[K5=:TRR7>?5* M8A531E:B74LY;M0.( J^>$:^D@F'4RJQRD* F, 9%QX HG>,75]F\A'E#9[1 MV2V^EXV+O%FY1[7.GK';INSL14*03F$@&Z"(].N8N%76HJ>\_6==;_DD7?\ MM7@?M+R>7[Q4VDX6^=BD\RN3&M>-T1QVM-$D=C_7'W>U26P8F<917U0H%JOB MOK1;6L1R[KWY"KF;%[5B=AU@./4"B48X452D]F8 U-Y[_B+\T?S3>1GX'[CE M7-?2"A;XJ=Y:MXV\]M#[IW3:/J9K.F?=0^LME^A+%8OHWZQ:9V)4X;_L:IQ$ M[/O/?)^=:M_]7:J^GZO>?M3*+?\J#_P#DIR(_NDS5T2*8 M_OWGY\;E0B'4A6MDWO:C]%(YF\%2=47F*?NU0*(D2(ZV5$4"(1 QO8)CN0Z! M[>@_)CHD"JOS_P">^Z/*+O*EQL'196+JL&[<5C26EJS[Y:IYQ)6-TU3>RLB9 MBS36L-ULQV;9,Q6[[)M/NR;- MF V#M7W15%VE!R+A@W8P-&0?MS'0>HU&(1[5E$S*(FDG+PR1SHF3,.N3J_<4 ME)S$# & 1_\ E2_1V\O/O-V#]^9YE'YD"B_XZ.9;'@AR0:;[D-?NMEMVM+M5 M2&L,[(C55CGL9&)2O@EEX2?(4K3W/VI^[B)^[]L7I[=LE54(3]?K/=4_(WL/ M]N,;_=9F'0Q4Q!M+XFS97041;62^;'D]BMF1U $@.D:W#U M'7Q#N$ 'N3]5\JEW@'>0Y0$IGE^\5-(^"O!^_>5WD'.[DY"\A:0FRG+*K9=E MM!O]1D=_7E%B9)->.K.LXMX>2IE>*R:%8MW[UHS8QS--,&+5RDD5,N3?2J(% M\&I52NT2K5NDU"(9U^J4^!B*Q68*/3%)A#0$$P0BXB+9IB)A(V8,&J:1 $1' MM*'41'-)3T& (07#NC(JF! MA)RVZK7(H=Y@(=Y!,]:1$,J*?[4QDT;$_ !'VE P@'RCFRWXD9E3X9BJ,V?' M3D?>2)$"0L6ZH6J.EP+T.HSIE%C)A@D8WR"1%>^.1*'V!4']G)/F$67V?P"_S!] ;$XO6"1]6?T=81MM)075_=5M;[!>.G;] MDS2,)C'2KEZ3>*KG]A2A--R 'LZY)KC4(LD9@4HQ^?+D'*I$0ITNG<5W&*!U'KFV"HJD+'.QN M/$7Q3\->XM!QI6QE]?<+MN,[&\: 'H2MVE->V6=O4RD/:!C(RUODWJZ?=U,5 M(Y2]1[4J@^##]*'QM_P!EW1^ 39^;)_*0Z$.:2E6_XG7^C?B1_'?: M_P# -+S9;\2,C"\6WEPJOCQU3L;7,_I2P;/<7K82=V0E(>YQU:1CD25N)@OH M]5J]@98[A43QHJ>H!RAT. =/9US*4>H$GOZSKK?\DB[_ -J\#]I>8^7[Q4?K M.NM_R2+O_:O _:7CR_>*EE?6-V1V7K77NQVT>K$M]@4:IW9"*77(Z6C4;7 1 M\ZE'K.DTT2.569'X)F4*0@'$O4 #KTS6^' I[G & 0;_ !"_Z.V4^_+K#]\G M,SAS#(I_AD_Z=.3GWIJA_/!7,I\B(N09J*, 8!!=\00DHIPPURJL4/_ +<[-^E*27<7,3YO1KR7_O.(_P!Q'2[UU1E+ MM%I[7*.XL=OZ/N>>OW6C;3Q'K(K^.WC6=#M["P=W1-VF$P>LWVG>F[CVC\AO M72-U#[ ^S[&?!]^XRCW;UE2Y^;9?U/&LM?B9RCZ69QGV$V\XH=N>@GIEV#^@-L3W?GPIJFJ)>75<88L76-/9YTEY MC\'"-I^T\H/6AW4_M5O2WV_TJYU:)HDGYU'\-S.FJ3KX/[O!^4O&-R5]/P() M\[.G2L8 P!@# +Q'B!XC?X8N+438;+&>Y;4WF$;L*Y^\(@F_B()5H<:%45^X MI%DAB(1Z=XNBH4%$)"2YB84^K0],ZK%FC^& MH]>OH(G'V>WH _8ZYV$],<9/NC;:Y+!R&_HI%?NM'4SUI2C'LE=4NT[350Z@( "0;"L"(]HC[!+ZZ)_D^SUS^'U(2B M^[.1E'L/ICER>3F-?1]ZNK]U,EBS@D[/C & , K M)_$&>0/[GM(1X1ZMF_3NNR8MK,[QD8YQT<5S7#H05B**=5 W>WDK\HGZ[Y,3 M%.6%3*F)#R/P\_ +ZO03WG3M"$[)NRMI2K: CI%OVK1E:.9:,M MVQTTU2B=)S9%"*Q4:H'8<&";Q0.]%XD?$WX M-9K*, 8!0X^(6_2)2OWF]8? MO,WFZ'RD+6'B2_1P<2OO9?\ F.>S7/YBDB^8@YPO#W]*AH7\].J_A92S?+Y6 M0Z*-XIE=V-2[=KZWQR88G'H/0KJ/>*$Z_*'= MUS04YV6NINY^+CR2QYYX[TSCCONIY6K8*21TE;9JV356AYA\U:A[#)W'64X+ M]B!RB!#N4%.WN* !N^:)#H?6;8]-J6MI_;DQ.,R:^K=)D]B25C;JD78A4(F# M6LCN9;K%,":[88= RQ# /0Y>G0?;FDI0WX,4>Q>3/RM-M@WY@=_ RFR;%R.V M>Q6$7C*-I-3F$).OTY;O+^[0BLJM"ULI1$# R6]@]2YN?PQ(7LMV?T,[<^]C M??YJRN:ES*<[/Q=_I#.('W\*?_TH^;GR9#I-9H*5ZOB4_P 1?5'YV5%_ _O; M,X+=QQL7JS:C=+ MNJY^@K,C%/"B;N(V:"\4^:!CCD@^-"FN7PUW*#Z5J>Y. M(EAD>][579=RZV075[E#5Z:685_8,4V Q@!)I$3XQ;U-,H")U99R<>@![;-> M)$9_^(MY-_[VSD=9Q M+V-]>O>K1%1K:8?Q?U0UKPBPF#J)0 =S=%4A M8NL7PQ](3K\X>JQD3>XN. MC)7Z/L@5][*1DY$+/VB13+MQ%%1!\F4H)JD*J1X[T^N;% MXJZ^K#Q.\5F.F8C?>;L'[\SS*/S(%-CPM:"T_R3YL1VM- MX4>-V%15M87^;5KLJZE6C0\K$IQ1HYX*T._C7GJ-17/VAZO:/=[0'-DFTJHA M;Z_R>/&I^2A2/^_]@?;AFOKD4\=:_")XS+4PLV;GNCN&5.7K["KM%D__ (<=<@5H?*/XG[-XYWE3W]H:_P!OL&FWUJ:1 M;"<>.BQNR=2W,Q%Y" (_GJXE$HOX^2*Q5%C+-D&*B#E($%2%4,@JXSC+JX,A M/'X.O(I<^8^J+CJG=])KLUC][A1PH;&<:/AR*3LY@#F+\J?QV>1_P"=-N#\+5BS?X$.G1F@ MI53^)YJ#UQ7.'U]11.,=$3>YJA(K@01(1[8V&N9F%1,?Y"G40JS\P /M,!1Z M?(.;+?L(S('PRMV8OM#\F-<$6(,G6-N5B[.&_=\\K&]4TD$T6 @C^T.XUVN7 MJ ?*'M^QB?,(LV9K*, 8 P"LA\37<63+1?&37YU2!(V3;%LN+=#K\\S*DT\L M(\5[>O[0B^P$ Z]/E-F<.9&>,^&'J+QK3N8%]52/]'SUETW46"XE$$Q>5*+V M',RR1#_(8Y4+JR$P?\D!+^SEN> 19JV=_1ML+^(]L_@%_F"YE.?MX4?TGO%G M_P";;,_ ILG-L_E(7WN0NEZUR*T=M31MO*7Z VA2)ZI.7(I%74BG4DR4+$3S M5(P@4S^NS!&[YMU]@.&Y!^QFI.CJ4H,^.W3 M)944FC&%F9SZI3KI\J;TQ/&U*UL&1>Z:]QST M3MG>=I%,T-J^BV"VJ-#J@B,L_CF*@PL @H/L*\L4T=NQ0Z] %9P4.H?+FI*K MH4I2^%C25AYB^1EQO;9 *6!AJJ4G^1=^EW:0G0E]GSDZX7I:2AQ[_2D%KO)* M3:0#[#$AU2]?DZ[9.D:$+?7D0_$+YE_FQ[M_!Y8,U+FOI*4IO!A^E#XV_P"R M[H_ )L_-L_E(="'-)2K?\3K_ $;\2/X[[7_@&EYLM^)&:R^#[QU<1N9>BMP7 M7D1K-[>+'5-M(U:"?MKW?ZH5G"'I\#+&:&:5&S0;-R87[Y4_J*IG5Z&[>[M M "S;7($V'^1-XPOR?I;^V7=?]X.8=FJ'\\%#JXHV;@'4(1-4%#Z[V'LNG." ("*"KZP#L J0@ B("9"\D/[>G ML/E]2^GRPNZF1DM467B8]U>]1M^17\-EKZB>C/5HZCV-Q,.+J\#/R[#]SE=^ M]4_!DI_62^9P =JQ@# --^>G*:,X@<9K]MLZK4]M,U"JZRBW/8<)?8EA0X2]>0^UVR+W<#>>+H*4ON'5YN3)?P,>VTY M\?!SJK<'X3G%\JG$O>[N5C]J>W6=NEN+U3I\G$@_X>5=35K@^<;:4KTUXV[< MTN+1S]):5DIV5DIR9?.I28F9!Y*RTF^6.Y>R,E(N5';Y\\<*B91=T[=+'44. M81,8YA$?:.>K-BQ9Q;$,;&C&&/;@HQC%448Q5(Q2\$DDDO!'A;E961FY-S,R MYRN9=ZY*&*/T^3V![ #/,,]JQ@&$^1NS&VH-*7^ M_+N"M5XV*;14.L8W8!;+;96/I]5+UZ@(^I9)YJ7H @(]>@>W/I-H:+/<&Y,3 M2HKJC.;E-?[.U&5V[_W<)'QV_P#<5O:FS\[7)RZ9V[2A;?\ MK\XV+/X;MR" M,V9\V?8C ($_B#+BC%\6=3TDBI2/K=O!C+BEU^V%C'O]7^?=MF\7BFJ2M+\?7&B)72,DJ_J$U;1[PZ'.E>KK9[HT5'[)BG9 M3R8D'_[G3[&<:=\\^.H]U]9OQ=8PR(6OKLV;=EK\,'7WG,OIDTN6D=B=NXLU M24\2Y?\ JRNTC+/%4RG,UCF[ESVF*B(94JN@*+G#/CSM; MRL\Z':^Q)64E&=GLC[;/(>]I@HB6*IY))%1_%Q:HB=&,>3:BB,)"-D^XK),Y M#$3%LT4 NUM11#H;5FM0%,KD!4*K$,8"L5:&C*[78*,0*VCH:#A62$=%1;!N M3H1!FP8MDTDR!["D* 9I*?MX P!@%#CXA;](E*_>;UA^\S>;H?*0M8>)+]'! MQ*^]E_YCGLUS^8I(OF(.<+P]_2H:%_/3JOX64LWR^5D.CUF@I3Y^),XM_0&P M-2]>3KZP^$RC\;@L/7=;RZ%XZ6%#WGLE1TAKY",N#"P)$ QU"QSRNNX M6JF[_P#]9*F\'V=.@WI^*O@"4CX^2\_'^C8M^648*I+KI?NJ.M M-=.WT9[RV,QOO\U97, M5S*<[/Q=_I#.('W\*?\ ]*/FY\F0Z36:"E>KXE/\1?5'YV5%_ _O;,X_BB0SQY%MC3OD MF\IX:PU=*)3=>+=JKQIU3(,U0D(U2* M(D;O,0A39(_#$%[?6NOZUJ?7E&U?3&01U2UW4:[2JTR^:)F\)6(EI#1J:IRE M("J_NC,HJ'Z )SB)A]HCFGF4K'_$]_\ A3AO_&'>/\&ZLS9#F1F9/AG_ ,5' M?7YPJOX-Z/B?,(LA9K*<.HX+U+K0HILPWS#QK;JO9J!')$;1 M>PP10+WN):AH 5O(G$IC'A.Q4QB)QW0^R$O AK]\/UY%OJW,(\%=OSO; V)Z M^D^/,W)N>U&(LCM1:0G=6G76-V)L[,N95_#E$2 $D+AN J*/&R9$X^*!;US6 M48 P!@$?_E2_1V\O/O-V#]^9YE'YD"IQ\/3^D2BOO-[/_>83-D_E(7Q\TE& M15>;1O#N/&+R=&9*CZ;=AK-Q'G5 O>E,$W)KPD69N8>AB+*.U"ICV^T4SF*/ M4HB Y1^8%=KX;!9^3G'M%%OZ@L%N+ET-(%ZG]$IDMI:<%FJ8 #L%P S9)57O(=!TIBG*4Y#%.0Y0,4Q1 Q3%,'4IBF#J M E$!Z@(9I*?ZP!@# * GG%Y=P_*7F;*0=(E4I;6F@(=355;D6:Q5XV2< M/]A61@J3N36;N)XY8Q)9,QD7+:)173$2J@([H*B]Y"UWX>N+\AQ5X*:NJUEC ME(J_;&4?;EO[!=$6[MA.7I!@:'BGR"@ LWDH.D1D2R=I'^H\CZ[Z\TH@EVMFNT*&WCH2PE,5(/1;?3E:6B7I1-VG=._ M?5/G"4XYM@ZJA&?ZYS^3O_$!XL>)>DFEA]]VC;WIHCD,F1T"K\&F@C1\7 'G MB]_4RFRI5W%6(I@#H"[ Y>A0#H)1I*O@"<+P'\8/N#\(HK9$W'>Z7?DK,_=, M?J+)=CQ&B,TE8?6<:
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end EX-101.SCH 4 zbh-20201106.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 5 zbh-20201106_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 zbh-20201106_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document and entity information. Document and entity information. Document And Entity Information [Table] Document And Entity Information [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Common Stock [Member] Common Stock [Member] One point four one four percentage notes due two thousand twenty two. One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member] One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member] Two point four two five percentage notes due two thousand twenty six. Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member] Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member] One point one six four percentage notes due two thousand twenty seven member. One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member] One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Amendment Flag Amendment Flag Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 7 zbh-20201106_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 zbh-8k_20201106_htm.xml IDEA: XBRL DOCUMENT 0001136869 2020-11-06 2020-11-06 0001136869 us-gaap:CommonStockMember 2020-11-06 2020-11-06 0001136869 zbh:OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember 2020-11-06 2020-11-06 0001136869 zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember 2020-11-06 2020-11-06 0001136869 zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember 2020-11-06 2020-11-06 false 0001136869 8-K 2020-11-06 ZIMMER BIOMET HOLDINGS, INC. DE 001-16407 13-4151777 345 East Main Street Warsaw IN 46580 (574) 267-6131 false false false false Common Stock, $0.01 par value ZBH NYSE 1.414% Notes due 2022 ZBH 22A NYSE 2.425% Notes due 2026 1.164% Notes due 2027 ZBH 26 ZBH 27 NYSE NYSE false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2

Document and Entity Information

Nov. 06, 2020

Document And Entity Information [Line Items]

Amendment Flag false

Entity Central Index Key 0001136869

Document Type 8-K

Document Period End Date Nov. 06, 2020

Entity Registrant Name ZIMMER BIOMET HOLDINGS, INC.

Entity Incorporation State Country Code DE

Entity File Number 001-16407

Entity Tax Identification Number 13-4151777

Entity Address, Address Line One 345 East Main Street

Entity Address, City or Town Warsaw

Entity Address, State or Province IN

Entity Address, Postal Zip Code 46580

City Area Code (574)

Local Phone Number 267-6131

Written Communications false

Soliciting Material false

Pre Commencement Tender Offer false

Pre Commencement Issuer Tender Offer false

Entity Emerging Growth Company false

Common Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title Common Stock, $0.01 par value

Trading Symbol ZBH

Security Exchange Name NYSE

One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]

Document And Entity Information [Line Items]

Security 12b Title 1.414% Notes due 2022

Trading Symbol ZBH 22A

Security Exchange Name NYSE

Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]

Document And Entity Information [Line Items]

Security 12b Title 2.425% Notes due 2026

Trading Symbol ZBH 26

Security Exchange Name NYSE

One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]

Document And Entity Information [Line Items]

Security 12b Title 1.164% Notes due 2027

Trading Symbol ZBH 27

Security Exchange Name NYSE

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details

Name: dei_PreCommencementIssuerTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details

Name: dei_PreCommencementTenderOffer

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
+ Details

Name: dei_SolicitingMaterial

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details

Name: dei_WrittenCommunications

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Document and entity information.
+ References
No definition available.
+ Details

Name: zbh_DocumentAndEntityInformationLineItems

Namespace Prefix: zbh_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=zbh_OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=zbh_TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=zbh_OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 5 95 1 false 4 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports zbh-8k_20201106.htm zbh-20201106.xsd zbh-20201106_def.xml zbh-20201106_lab.xml zbh-20201106_pre.xml zbh-ex991_6.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "zbh-8k_20201106.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 5, "dts": { "definitionLink": { "local": [ "zbh-20201106_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "zbh-8k_20201106.htm" ] }, "labelLink": { "local": [ "zbh-20201106_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "zbh-20201106_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "zbh-20201106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 3, "memberStandard": 1, "nsprefix": "zbh", "nsuri": "http://www.zimmerbiomet.com/20201106", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "zbh-8k_20201106.htm", "contextRef": "C_0001136869_20201106_20201106", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "zbh-8k_20201106.htm", "contextRef": "C_0001136869_20201106_20201106", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 4, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "zbh_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and entity information.", "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.zimmerbiomet.com/20201106", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "zbh_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and entity information.", "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.zimmerbiomet.com/20201106", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "zbh_OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One point four one four percentage notes due two thousand twenty two.", "label": "One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]", "terseLabel": "One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]" } } }, "localname": "OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember", "nsuri": "http://www.zimmerbiomet.com/20201106", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "zbh_OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One point one six four percentage notes due two thousand twenty seven member.", "label": "One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]", "terseLabel": "One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]" } } }, "localname": "OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember", "nsuri": "http://www.zimmerbiomet.com/20201106", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "zbh_TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two point four two five percentage notes due two thousand twenty six.", "label": "Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]", "terseLabel": "Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]" } } }, "localname": "TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember", "nsuri": "http://www.zimmerbiomet.com/20201106", "presentation": [ "http://www.zimmerbiomet.com/20201106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001564590-20-051650-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-051650-xbrl.zip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�$ZK^&'JA)>^V)K721*>,G\T=OQX1'>G3E9N M9.:"6H<6*!N4N;3:*Z0NH+<6]#8R=0%WM4#9G-2ENTI7&-B-219%4Y?]*TI6 M>$)9R_P*>I&W9">0!GID]$;F>6@3J(%REAU M#SIKA+*160VXJP7*6'4/.F,&YC& [;HXUE0!C ]#-QIQECK?L.N7[D4F0U0" MLRQ%K;EO8Y9EXR OO^0>$RR5U L]::L:RN9,L&PWVQTL,2Q2EO6975$F+3GE M+O>OQ3'MF!5![0(H(RM9&OE&$[W1IK';R,P$W-4"97,RDT:];[75 =X0>F/2 M9 .3)M=T[2C&22EEJS.J%UJ@;$YVLMVH]U;(3\!O3)JH *AJ@J$G;55#V9S4 MA&2Y@[EL3)I4.BW9<]UH$J8)&SNWCEQ&+S8K=MUXPCW&OXE]P#"=HGLY24_E M4 UEDQ*69L-JJ8.\GOS&P2J:"X:>M%4-99,2E@X-5'60UY/?+TI8UI4Q^3CS)V8D))ARSF)+WB\8^ND%^O#;),9?,V4(/TJE6A MOD/_5W7YCX[RHYHELJQG'<;0P06WNRLXX/4*T@H> <-BO=!GZ1%\ 7R!V9;( M4BWX@EDZ5L+T$9Q!R7-*AJ9HQSQEKI-]]CP=GX7-#?UKV6^QMXG MD]FSWMUEK_UZ-_!#OG.5W5/#KK_>O>9QZKM.D$L! 2"&%9F7ON)#X84.)'Y* MU)2FT O0'G4NB :4,-5B9KA1:^D0+G2[_1+FU! NE#9PD#N6KU%P)Y4QU6)R M"7?RO855-3$;6/S2*C@4K==;/0-P#N P"KSE$'\IO/LBS;P(HIMD(=GQS1':T%RMA(&W36"&4C^QK!72U0QD;:H',I.8KR MBZ^4.0]HCQXP]:,P86E$24F2QA-QJC)$,9287S*AEK=MV[;54P=Y M/?F-]5::"X:>M%4-98/66]E-;%Y7J"SK,X^B9HX2R756XUCT[:6W-38.Z,UR MP17_<^*/1?*B3EYN9.Z":H<6*!N4N_3Z*Z0NH#?VME,!4-7T0D_:JH:R0:E+ MH]W&@4!*IBZ87EEER5'6ZB42$W;%O4O.$IZF <D*N*L%RN:D*\TNYED*9S+^.?$3.=_"H@M*7E(>!-Q- M)TXPFW5A43O5P\I(^^@174AE38??LU5Q) MN]\H87T47(FNBZ:>P5:=?;,O_- )W1?FB%A$5-4#:R M]Q#8ISF^TI%X4OR5(PEU+)8I(A>H&Y%.6R%%!;"VH;F:6 NUJ@;$Z6LMUM8X*[ MT ENS*2L'5ZQM=IX+DO)=K[V^#!5)_\V,DM!54,+E)&E@-J:4MO(+ 7*_02RE1\CZ41/4[D_G$5!1Z/,9NB>4%)3\E0 M#65S\I3M1JMG==5!7D]^8UV*YH*A)VU50]F@/*71ZI9PM)EA_,9L2H'K4OAH M'$2WG&?I"G.CT9B'B2.7UX\#+%R,,!^C>4G*$&W!?$QA1UGWK8XZP.M);TS':*X7>M)6-93- M26BV&VVKI0[P>M(;LS$;A??C)/%#GB1BYF7HA]G$BTOOI<>FFQ(_)K['XWQ& M)E\%HTX6;V3^@MJ(%B@;E+^0WJ'#6IG\!1,RE=0+/6FK&LKFY"]8C8C)F,HG M, =\F#(_229.Z')*5Y(5LA/,KE2RPF2(6&!VI:CLQ+;15:U.=H+9E4KJA9ZT M50UE9">@=NG9R;K2P?E4A VCV./Q%,$D"GR/9>]C\GG&3DQ0Z9"RG,C]PR[\ MD%(6T17FN*E_[:=^":?=SZ HKPOO_;Q'/2OZO(?(Q1(B0F9=1A#!P>\ MW2EA)C30<%L5/Y,SG17 #< -F6R++L> &P2I,;W( F.Z89FIK- MEO9,$NXQ/_RQ+&V]QD"65G(-: J] .U1=P#_K82I%M.XC5I+"P??:+:M=DFB M!A=?!NK(].!*8*J54T&XDN_FBOVN9<.55"5;K.9$GAJ #RXNN)NRZ(+Q;^Z5 M$UYR%CLIER<$R132";WL!_[GQ"/;3&S&K M]^/Y&9:.5;*>9T@GMQ(3<";XS6:KCRV@3*,WUH^!NU5%V9SU8]O-.E;U*IF^ M8-;IY8#O/Y6YU-B0T[V&HE4QNF!C'ON1A^DF]20>-49C+('IIGGK=!K=$L[_ M0)$1$T[Z0PUGH+PE,.$T;YUVR[9Z< 8JC N5UI9YT608<&9;NOF%9_(V3G]= M/6,K8&V9ML90K2CW@@4!"[;1V(O_I(Z57K:L[$6&TL'#]SMEG%7_E(=_4LLT M'#,ER=LSZ1X\"3Q)V:92R).\;%69L9ZDW; 56I]LM"=Y/%>D!ZA6?^+WT&W4 M2_<>A6.ZZ89#$S&]YX[+=[4F&N%AW@8[E#08@''%6Q--Q!0BKH 1'J9,L -$ M'(G.#\+;*P3=]\ED=OMSUVZ_W@W\D.]<95=JV/77N]<\3GW7"?*:A0#\PW;C MS?NW]!6YE;+_VO5&G\7$N!NFC!G/(ZC;_[(27EPRWYJ='J,GB?(SBSV/7IC M0"]Y+(V80W])Q='&@9_ZE]FYQO2YE,>*##$D8I"M*F*\W*HOP PJ*X\QTBCP MMHH8+[>Z"S!7CF^"(154C&'AX/#DW]]<9+TE-/MQ-P3:'P4 MCRI?Z=-["9?WXGL6<[<"[_;G5XU.G2@I7OX@C%,EJ*3WPZ.CP2G[>'AR-#AG MGT^^'!P>_WI68X?'^]:3)2789*,V.29+G.U]&9RQC_]FOPY.?CW=^_KYW[!& M.=;X='+*SC\/Z-_3P8 =G1R??SYC@^.#P0$[&WP]'QQ]')QFBM)2>7+T%J0:]M039 M%*DN:5/7\ZN8=OCP>>J(D) &MPM%='^2MP%^*"STH@J&0^J MLNBZ"#ZKIB3&8-]=ZH5P5&T;W]\*!>YJF7@0U!BDJ34^U#V@K2E]CW^50(Z@1U$@5->I_=Q9;6S7Z%,5TK9 -OKE73G@)88(PF2Y, M2T]:[W_Z5/^T7_#9%56$>&_$*>AQDJ4IOG%D']FKH(K KJ@LGB=,_J0. MPBMOHKMP &.E4&_4[$;':JN#O:;L5DU$H,U@+[19;=0;M4:W;]GJ8*\INU43 M$6@SV%M=F T2Z";$V3AZ:R+.K]5!%,0M!.:5CYNHKBYWK*XZN(/>T&7HLCH( MJT;MECK :\KOY3O#HH[J5O%[MIK&;TBU>1JB*955@]F@ M5J15ND-!;SWH;8Y<%[[CT8\?TU-%W/<2WV%?'=>_\-W"N^Z4V3%>84DIHH=T MF5T&H>Y%K05?AS7T"'!:G14FX-?L!]3;_-& D0&'H( *P2$H8PHXA$6'T.S! M(1@U,N 0P'-SL/^^W+_PY/+J2OXJ35X8"+H,!&P #Q=@)O;=[YZ,9J +*'[% M/09"V0,!+@ NP$SLN]\]A\XX%[#=*&$G+(R$4K9B@?R7+T&&D[Y4['O?/?C/ M./EOH.IOX$" "WAQ3]R:#$\M"?.BR;#@#/;TF[^Y3Q*G4"EHR_UA5JU_MHY MO1>H/3K5_IQQ=&Z.6/Y4JX*V.2C$4GH$4+6^W2]ANX2G@J@G!4W'<:/>47G8/]J*]V+XM1!]VZIC(!@W$ P3 M_.4/KP'%=:'XHSUW9FM];#;")U_M(O.;)TO8V=/#(2R!X+!6I^UR[U-'7I6^IOG7_]@C^#"X[U> MN/=A%'@/'G?>]+AR25=^T74R^ODIW;'[(A*O(@^O&IUZI>\Z&UERG.5"\\M6 M?8NY/ B$DI,NS7[/=4K^GDM@QH>9WN5*Y49!X(P3_F[ZPR[+G4F]GNV .>V# MI3?05>B+[,Y6NTSLKH ]Y?B L9^F7*NKOAT='@U/V\?#D:'#./I]\.3@\ M_O6LQ@Z/]ZTG>Y-ADXW:Y)@L<;;W97#&/OZ;?3T].?C7_CG;WSL?_'IR^F\8 MI1RC?#HY9>>?!_3OZ6# CDZ.SS^?L<'QP>" G0V^G@^./@Y.,]5LUFO,KMMU MYH0>_=#HPV3EF&S;#QE]5^!'85)CD]"9>)1^>&^>M$>I)NA;#0UMH%K+IFWU M>X"YB,[8HG)]V($.IP65=0.Y9 M-J0:]-859%.DNJPM8&7OD6)[\6K/]GEJ _LY[&=MD25W1=I-J_$=VTSWA=/. M+N=7,>?LB%Z\2MB [L-C9WR<\M&0Q[,VU_(6G,'EJB)"0!K<+7DM\!H/U #V M8'-5E5B'L*-L-D-'2MJWQUZ!]2AS82!HBCSD'ZPW#_G..D-XC .,@XHB#_4' MZ\U#/IN[AOPK8@X,!,B_&MAC-EP),V (J#$;;I<[&]Z?3]($@LL6HWA4I)4O6A :+4W*[2KHMK54&?C:&B7\F$6I&F#TF24\KS.^@@/0Y>] M9=L'W"WKP SH4 5U:',C ,HTJ\N:VOW\OU$P&7&2I2/_&T0)H@114D64NL:& M2U]CW^40(X@1Q$@5,>I_=^9:6S7Z%,5TK9 -OKE73G@)88(PF2Y,2T]7[W_Z M5/^T7^Q9$E5$^)\AY\G2]-XXJAO<"K=LAUHJ68M;0U8DS#^I@_"JYT14]Q#4 M3JMG==4!7E-JJZ8@$&:P%\*L-.B==F.%\ZE!;3T4!,(,]E879G/4>;MNM=7! M75-Z+]_= EU>LH%('40UY:QJDKSRV1'5U>2&U5('=] ;N@Q=5@=AU8B[ZD$1 MU97E;=OJJ8.[IO1&J Q)KAK"JDGRRB="5%>3ZR@M&T=O#76Y\.TN=.\?^NR/ MEV\?VCBHFC!6M:-AH+?JG*:M1331ZK6LACK @]]0Y^K""O9"G=>KSNV^9:L# M//@-=:XNK& OU'FMR+=7F+0&N_5@-[09[*TNS 9U%'6MICJX@]X0Y^K""O86 M K-1;47%[\)J&KV+WU\2N@SB:@BS0;U%#:OXG?U!;XCS)F#%!D5K1OC,&ECG MZ(DK5P[0T:D'S.;,DC3;?70L&\=OJ#/86UV8#5+G5@^[81C';Z@SV%M=F U2 MYQ4FL<%N/=@-;09[JPNS01U&+90UC*,WQ!GLK2[,1G4884.Y38.,C8MT%PQ- MB:L:S 9U&-6QH9QQ]-95G+&%T9H1/J!+.T&-G8W]D+.?G=%XE^T??5J^Z0C- MZL+LT'JW(4ZF\=OJ#/86UV8S5%G M[)QA'KNAS6!O=6$VJ.FHCQ7:QM$;X@SV5A=FHYJ.4-78-,C8UDAWP="4N*K! MC*8CT%MC>NLJSH5O:S3?8<2&4>SQ> IA$@6^Q[+W,?D\8R/" M.^CFF6L,U*IU*WZ'YJ_J\A]H>%$+O==A#"VBF$:KL<)1;6N6_^4%"0,#_J"" M6,,?J&\*^(,%?]!>9:8>_J#Z P/^ #PW!_OOJOTJZ&NA^-N-.A1?]6DG9<1^ MCO(NO\F\H]EE3%_3_GOZC @3]A_Z#]-ICWT'X_T#^5VC^Q4" ^D/] M0?J*8I]UIT'^2]XZ"P.A[($ %U#ZMEO/=,!YT608<&9;VDV[G$>I$Q3>SOD, MY_6%6K76V3F:"]0>G6%_SC@ZMT3\I(Z9%N;'-FHH+<*G1JUO]TO8VN"I$.I) M/=-QV)0D<7 G"N@4W GO\:%#>.XH_VVIFM]4VKBX%@W$" UH/BFE/\L;XZLZ5^V[8Z M& AJ]]5!YB'S58.]Y.K-(PUT9NM\?84#VS$0=!D(!FM]UBGW-G7H6>EOGG_] M@^V!"X_W>N'>AU'@/7C<>=.O@BNNLYGKN%$0Q>]>.9,T6I*9+Z7A^V',WGZX M=_]/>1%Q^PU[_(Q7D2.LVW[]Z!,6.;R^.I><-9KOWSH?6'3!;+GA\]__]OXJ MOI.K2[XSC+GSQXYS0:/JG1/<.+?)U!/4Z]FNE-E@E$,SUZ9?MNI;S.5!(,2? MI&SV>RYM\O=<-;,!.Y/(7-S(O($S3OB[Z0^[[-Y5IUVS] :Z"GV1W=DJMSED M>F<%="W/CX3-LO_WPZ.CP2G[>'AR-#AGGT^^'!P>_WI68X?'^]:3G24G7\>L./#XP$[.CD^_WS& M!L<'@P-V-OAZ/CCZ.#C]^56C4]]MUFO,KMMUYH0>_=#HPV+E6&S;#QE]5^!' M85)CD]"9>)2I>&^>M$>I)FA;C8Z&1E"MM[-I-6S 7$0+;5%U 7-![DLNKU ) M [U![^J #*D&EW4!&5(->FL,,J0:7-8%9$@UZ*TQR)!J<%D7D+M6%U(->NL* M,J0:7-8%Y*Y5AU2#WKJ"#*D&EW4!N6=U5SMG'?0&O:L#LBE27=:NLUDCDV+[ M_VI/]WEN _LY[&=-EB7W6-HMJ[GD8;#:V>78#SD[HM>N$C:@V_#8&1^G?#3D M\:QGMKR%;G"YJF@0D 9W2T6TOQ)W 3[HK#2B2H:#QJSCQB$T9>X/UUVCD&,P M8#!4&'NX 3#?3.RS66>X 64,@L$ -V F^F!^F5O+=3=S-BL& P9#U;"'&\!, M.4JC2HX"16;*[;)W(UJPCE56 MO1KJ[&@-]5(^U-(#:46ER2CE>9TU&FX?<+>L,SR@0!54($U+'@JI4N^[K1K: MBM+_1L%DQ-E;=N1_@RA!E"!*ZHC2]QH'M!6EK['O:+/:J#=K[5[7ZJB#O:;L5DU$H,U@;W5A-DB@MQLM:_E6,!#\92@OW^H" M95ZRCT@=1#7EK&JBO/(A$U46Y09$&:)<.40ARN:)\HK'2518E&UH,C2YMACK :\IO:/(F-;GP32^T[R(:' WVE#[FI(J@JG9ZC*9: MJQK,!LV$]'M-J_@M/4!PR+.&L(*]D.?U0M^HV=W."EV>H+@>%(= @[W5A=D@ M@=ZV$3^K5(PK0YDU7>D'*IL LTD-1O8J"Z9 <&BUJABK)B*:4EDUF$WJ.VI8 MMCK :\IO2+5Y&J(IE56#V:QVI*8ZP&O*;TAU"1I2^%Y'/WXT3Q5QWTM\AWUU M7/_"=POONE-FEWB%O641/:3+["^HH["K9HK^TKOT&Q'<].LMJUN2*"FX[:,! M(P,.00$5@D-0QA1P"(L.H6];+3@$@T8&' )X;@[VWY?[%YY67EW)W^Y9/8P$ MM:N>RHB]IJ50D-X,[+O?/0_-//GO0OXA_Y!_D%Y_[+O?/7G.//E?I1,-(P'R M#_D'Z2N*?>^[1_T9)_]UJ+^! P$NX,6]<&L^^O+17C@OF@P#SFQ+NWF7\RAU M I4.N]07:M5:QN?T7J#VZ!3[<\;1N2EB^7.L"MKJ6G6WB8UPMW.HP"[\'#S:L=KJ/Z=3(V2&[D@^.7K?H6GIR\*_]<[:_=S[X]>3TWS!*.4;Y='+*SC\/ MV/'A\8 =_?_LG?U3&T>V]W_?JOL_=#GK+5*%)WH'DFRJ")9C[@W@!7)O/?O; M(#4PNY*&G1G9EIL*YD8]UZC M))WDVV8ZB:=#-U@>?OMH>_AVG;>$1O#M<.%&BT#KE7F#U#-WB'(S)6 M#X!V.R%JLVJN"I767CA6/N\=E>^O5 M_NYP9,UG(UN=J/TG_>*VC)FX=CE.)M8JV"HN\:$CT!%"4A[[ MAWI]RJ_M"D\Z ATA).6Q?ZC7I_S:KO"D(] 10E(>^V<_W,=VH _XL1_>JKM6 MT%?=^Z5CP[RL^T3 ]J/#U&167]4A1!46Q;V"=:\'Q>IP+WWNA3GY8TZJO.?Y M[$#AUDL[J*O^-QX4H >MCWUNQ;K1JS1SGS4Q_=\'U_'D"F/"F+0;T\(; MU@>O7C5>'6SX4HD0)?Z?B;7YPGRO7=8U5L2M.Z+62NOF\L@V*?-?_5%XZ0LC MPKV^L[G=Z[:B'7^T%TJW;R:"-T,OWNRWZJWM1FBCC_*"P5\\7,N.//R5]K#K 937OHFB9!-N<=Z!J8*-]X\CH]>>,U+\0?(7J=W"Q^ M@FCMJ@I!UKF*!6*UB[Q6=2/SCD2 M5V^HXRRG#)D5[8[L=7I+#"D 7 ;@V#/TABNS(GMN;C=ZRVQ?@[@,Q#%HZ U7 M9D4&O=5L1(O?60?@)/OYH:AOEB$47-]DUG2Z:)?*&!AS<(KZYAA"P?5-9EVG MBUC0P)A#4]0WQQ *KF\R<[H(OC%FGQ7]^M-%%"]:4.*7[J/CT;8YNTDFUOPM M'M_\8 Z.7BU^X(B3K15JPK[)K&C#9*>U1W*).L"Q9^@-5V9%]KS;[2Y1 MO!; 90"./4-ON#(KLN>M9H?1LT=K=#ASF)8A%%S?9-9TW*C9IIH1SAR>-7OBC.G!CS2'5,WIPO,A3XMIF&S\_=Q]=-5+[=@RW^67MOVE4_V'B M&\ON7D5KB!C%M'N=&O)9%NH5]QV)GD% "%!K H+_34% >- \G=[N$A=V$A#" M[QD$!#C7H_V?V_TR\HNP_*U6:XD])KI"T/F43W;[>\@/W#_:+$CF\7^EVL\. M=>'_#_R_$?7H"O@__@_TTK6?'1W#_Q\>,WY>J?7:+ M_4N-(_E0Q%_]:::'&V1K;2D1PZ?.]EY[KX8S448R">$$_T: WG]6G_V2-X7RV_"-/?:G9KJ(Q&5ZBE]H-* MMW\.W>J,_K-G[;0;?7N)]!JZ D8?FLP8O4:C_\RA.N5&OTQ.#3T!GP]-9GQ> MG\]_]O2<@(^'YK,SS\Y)/==$;MG=7\W3-XN]70/'N;Y@V]ZD8Z& MGSS%S;Z/1^_B]_EMUV\T9I4(9TU0-"8ZGUB%P/G:RGYY^'14?_4_'QX/S+ MV;8Y/#Z('CVZ2INLM4U.^P'OQ[NGQ^>')N35^:T_^;D]+S_TAR[1CK; M_[5_9IZ;@]?[Q[_TS?D)[51/.[E6.CO?/SXW![^=GO:/#_[?7:/0(O6TR-9T M$D^';APZ_+;.<_>/JMZ=;5<$/V#S\)R>Q.F';S+WHLXN2@.T&)E;4:>'':\^ MS$5M5,43PI29( ?0LF2.=CO8,4$N"%7Q!(*<**4!FB 74LV0I=8N):P9>T?R MY@Q#K\B+Q3_P!N\@15[CNJ9>43^=\.$/^$.0(F]V^J=79V .>^JG5U2"'?X@ M1&3F>N M6621X8]USSHX_G \N57O\>3V7O0QU!(T?Y5FIKBVYOPZL]8Y^UQG+-H%*:H3%"8H*Q$\O[O@^MX"]/VACRIAR**M&G#\-P[95'C]]/CMV>E#/H!LS7X^BLS4. MK8=)-VKKY1@;4\?4?6J6P[$STLWO\>+FZTP-0$%<&I<6U"R>#+W)]\+4-[^X M/50:"W:&U.X%]L>N5ZVG4R,*\H]?NL::LWC;6W M0N]! *4AZNP.B+QND34>WEE_J%S;)25Z-24X^M **PJ.$F:;OC4-X7(3(HN< M9'H7+O$' JC,5B" >MLT!% ":"A'X-:W2MML1SN/:[S)6]GVQS9+!O'B"[22 M#LEJOE5PZ7S)K/RDE47 34K?CEK^Z [>H>=+;E+6Y_XHRJ70V$&P,BN*=EN- MJ.F/\$+Y_M8CA65<#^UUI%O?2I!F4Q;J#;[)K"CVM:.V/[J#-_'OZ^*?H/.H M_JQT]H_Z^QXMT6,.F]L)5!'[MEI+!#_X7O>\+^1#I9H=0^4R)W8@0V9%X:X= M=?S1';Q#/]>B6=8OKG>&ZQ"^R8Q)$ -7/.7K1CO^""^4;X^F?%+C'R<[UW&R M,T]B\R8>))?)P*/5>IDFX=NFB*(@N,RR)WC+P%OGVB='/(-4%4\@Y*U6^F;4 M\T=W\.:82[BRLO:)2,O"6&@,%G?=L[43M[N,R;ZY\P'E: MQ"./ENYQ"#;_5KSNV?!'=_#FS.;])#.$=;PI65!4],0H[, MA$$(%RZST##("<_'=?]:D?]G8I=8[Y2T*Z+W9K/-KG;JU1F8PS[-J5=4KH4/ MV@T\'OQZ$MPT3N\@7(C,0J=WWL4\3 *3"%5FPB"$"Y=9:!@4=+RSTXP:7UCE MY(IV;(+MOGK2^\!;!MY"#GIZ?7%MB(+ZQBEV0+1;K?0O_%$=N#G7(B36B; & M[\#%'PA^3/4"T]@WO 6&/T$G.CU:Z^22=O_<@0V_%=[8U^/:VK6+[-&-?4+6 M.'US#)4+G=B!#)D5A;LV9;K*QW8A)R9%84 [?VHJX_P@OEVZ,I MG]3XQ^%.;FF7QC2[?ILK8,UU?=KPUKGXR2G/(%7%$PAYJPYYN_[H#MX<= E7 M5A8_,0DY,BN*@5N-)78 X7O=BY_$/^IW=CO1CA\J4B=\WH4\$0[AF\R8!#%PQ5.^)@E^FJ9\ M4N.?H-.>WEQ8]#JYH8BG9[&/S3ZYTD-XZ,<\O;UR)^!#GGHUQ0^(>+*EAW!. MN80K*XN>F(0]QHC=$7;_ I-^AQ,PZO#FT&=@ M"Z":5<43"'DK/O"R3(8??'/@Q0]%?7,,UC[Q!SDR*XI_NU'#']W!FQC(H4_/ M%CZ7NM.(O1$9>R.*(F"#.F?J\-:YZ!GPJ4_-JN()A+S52M]>(LD/O&7@+772 MYUW($^$0OLF,21 #5[SQUXIZ_@@OE&]*>_JSZ,EISV5.>W[-O4;LC\C8'U$4 M!3N4>U&'M\[%3TY\!JDJGD#(6ZWT38I:J\-;ZN3/NY GPB%\DQF3( :N5OH6 MB7[J\)8: P6=^@SU;B.V1]C^"TSZ+D=@U.&M<^&34Y]!JHHG$/)6O?"Y>*H? M>,O 6^JDS[N0)\(A?),9DR &UG?>!;QEX"TU!@HZ^>G-'4=G43\Z]VC-'H=@ MYV_%J7]M?W0'[] /?'I[&T_ QSWU:HH?$.Y6*_TRQ5W 6P;>4N=[W@4\$0[A MF\R8!#%PM=*W2'A0A[?4&"CHL*;2"CT.P#[C:BM?-!H<_ MUZZR1W?=:ESPY-QG@)H*M0+?9%84ZSCWJ0]OJ9,][P*>"(?P369,@ABXZOE> M,VKZH[Q0P#V:[TD-@((.?7ZYPN?F9H#4]_0P^+';M\JD!XJ=:<-;2'W/Y_XH M2FE/["!8F15%N\82]SF MPR\AKH'#_.\!D*^:?8:%2&K^];WN0OT71]SV/)-FZV; M+SANQ>E.]WGM+?LFOK*FV?WQN_@GDUZ:5G60_K_^\N-U]J%_7]D7%YF-__TB MOBQL]GT\>A>_SV_[:J,QZZHSI"O S46:#6WV]V>-9V9@1Z/2+5U'O_OSO.-7 M?Y[;S, ]O\WN/&7V!B\&Z6@4W^3V^]L??C ??>KMSH%[@?L4]T;-[K-ZO>OV MFWT.DME3KBP.;VY/X9^'1T?]4_/SX'Q+V?;YO#X('IT-XEY_Z4Y=HUTMO]K_\P\-P>O]X]_ MZ9OS$]JIGG9RK71VOG]\;@Y^.SWM'Q_\O[M&H47J:9&MZ22>#MTX?OAM,%O1 M$G3W;IZQN>F<7I&77JL ;_ .1V2-B3CUKM;C#_A#."(3_L!;LL@RENI]DY7# M63A"H"(3\,!;LLCK"W@UBLK:ISJ.,0MBH5SEP9NUSS!%9>T3?Q B\F+A#YV! M.02114[\"'8*5,8?O EVX W>88HL,ORQ[ED'QQ^.-[?J/=[N==:ZH%N MXLQ))<]4 C#R+[7--XWJ/WGM_>Q4+BU.\E=I MYCYKX@_9>#*+5F&*BB?CR:LI9I-.\L+]E3]H8\J8,HM&H4A>-\>8!8M&/A MG?6'2C7[Q(1+[:VPHG!)!R& ABFRR&DG 52!R@10'UJ! .IMTQ! ":"A'(I; MW[IMLQWM/*[Q)N_/W!_;+!G$BR_92CHVJ_FBTJ4S*+/RDU86 3L,=8+.IOJSQMD_ZN][M#@OTQ=\ MVP/1%/A:[6CQRW@ ?-V!+^03IIHMXXN+G.':@V\R"_4'WV36% ;4=L?X87R M[5'\$S+Q\\TQB'_X@QR9-<6_5BO:\4=YH8 3 -=N&1SQ7,<1SSR)S9MXD%PF M X\6[V6:!/M_]47!7;;_/ J"G/(,TS&8!>(/[P'7SH$S+Q(_1I\V2A MUN";S)I"GYOV]?Q17BC@Q+YUQCY!!S^_H.[FUCK?9.EP.BC,05S8JS1++ 4^ M/8N [/K)E1[".0 :KJQ,!#$).3(3!B%B]%JSD"ZA4>NL,^"JI75*: &(04D0E_T"U8 M9*&3/P*@!IE9(=(0 C5+#^&$P4VL@?I_/+33C!I?6 /E[G=L@LW 529'['#W M^]I5]J@BC)!#H5[??RO"&7PS9:'6X)O,BF+?"W]4!V[.P!#\_%'8.W#Q!X(? M$[_@5/9HXBOED& M4S_\08[,F@)@@_BG*?X)F?GYYAC$/_Q!CLR:XI^; "Y^"Q* $P#]4)1CGQN1 MF?O@_0V#[ "N<@>PO41=; /?@=0YSHH1V!DR"S4'WR365, Y$9X5?%/ZC20 M^*=!9J'^X)O,FN*?FP NOA$(X 1 /Q257 *TVXEV_%"9Z^ ]#']L ZXR_.UQ M#L:C\,49G[81!21";\0;=@ MD87._0B &F06NC;DF\R*%C]]DQ[""8,< ?4M%7[9&Y#8)&$7,##IMYJ-J.V/ M\D(!]V@7D&.@S 3#E5FH/_@FLZ8 V(B:_@@OE&^/XI_4*2#Q3X/,0OW!-YDU MQ;\F>1 $P/ 4E7P,U*,UT*6N0V*;1,8VB:;PUVI0!M2C\!?R05#-EL'\#W^0 M([.F $@94%7Q3^KTC_BG06:A_N";S)KB7VN9^P !G #HAZ*< =V(S%]U'1*[ M)&P#!B;]%I<"^A0%.08:IF,P#<0?Y,BL*/YQ"$8?WE)G@L1 #3)C$L3 E<\! M"8**YH!2XY^@DZ"A7HC$/@D;@8%)O]5L+9$)#^#!;P3J7 +E)(P,F87Z@V\R M:PJ RV3"PW?P\4_J](_XIT%FH?[@F\R:XI^; )(*00 ,35'))T&]N1#I+.I' MYQXMW/\D(!]VCW3^.-2)Q]D2&S4'?P369-X8\RH*JBG]2Y M'_%/@\Q"_<$WF37%/S?]V_5'>:& $P#]6?ST__"G-XN?+]T'QZ-MK@6YNFDTM4 ^#'WM_J]S[Z[+WYU'P"_GPYR85 M?>Z/HDS\L 8Y,FN*?90!517ZA,S["'W:/%FH-?@FLZ;0YZ9]/7^4%PHXL6^= ML6^VW/E=$5^,K/N[8?)VJ:=[\##//WZ4^^ZD\UW7WY@_7F3FNY\^^M:/V6OY MI9NMFR_8;<7I3O=Y[<_U)KZRINGL-?[)I)>FU2T?\;_^\N-U]J%_7]D7%YF- M__TBOBQL]GT\>A>_SV_[:J/Q^:Y::O!Y"98!9-91JFYC+M)L:+._/VL\,P,[ M&I7VZ^SC[L]S.ZG^/#>O@?L(F]TYU>P-7@S2T2B^R>WWMS_\8#YZEMMM"?<" M]RGNC3J=9[4ZXM[>XT/7V4.N++)O;K_BGX='1_U3\_/AR5'_W+P^^?7EX?$O M9]OF\/@@\B@8;2[^_-.%.;&NL'X=9Q9$X_3Z:1P_S*=Q-.A(V_HT[1=86^H5>]NU/MX MG41"'_!MJ;41[7Y\"@&9L8\@1>Y%G=92VP;@#=[AB-SX]"@O+,-RD"+W\&G8 M%BHR/@W+4D3&IV%;JLCX-"Q+$7FG//^+4T.W2)%Q:EB6(G(GZN#4T"U49)P: MEJ6(C%-#MV"1H\8N3@W+$D1N1ST.?H"W5)$;'(6$92$B8]7@+5ADK!J6I8C, M^@=TRQ6Y$>VQ4@W+(D3&J:%;KLCL*<*R%)';47.YRH;@#=XD\/LL>>W1D01^ M[$.&R"3P@[=@D9G(P+(4D4D,A6VI(N/3L"Q%9'P:MJ6*C$_#LA212>"';KDB MX]2P+$5D#MM MUR1<6I8EB(R3@W=@D4F@1^6A8A,5BAX"Q:9K%!8EB(R5@W> M@D7&JF%9BLBL?T"W7)%)X(=E*2+CU- M5V3V%&%9BL@D\(/WYA+X!^G(/:T3 MO--Y5JOX>WO/?S 7:3:TV:V\>3I*AF;VB^:;1O6?O%[PZN34G+_NN_^=]OOF MZ.3X_/69Z1^_[+\T9_TWY_VCG_NGIMW8-JU&J['QSJ*W9VQ.W%D=BUOX2[T^ M2_Z7>D?UQ#=QYK1<3[-4K=!]O!'FS387-\2P<+_8!6WQA;:X"QFM>B/&3E7+ MX4E-Y450^4)+?FVS':1Y8=)+)J"3>.UM&-MGV^P0W\*W MA+*-'X779JNM1-M;,X'KM!5W[M M8BD3R?J[TL(970>O7C5>'6SXLN+@]-W/S:F]2;-EUG?7KNQGKB<6DFA5*Z\+ MV/ZF_&.#S?!7?UJ@MUAZVQ*% K+RJZPLTFZP5;J]O:CC3\ML<.2OV($:G]9T M055\/7Q?Q]2K)FEV]J(=?YH%4\?40U454Z^[!3#U69/L=J,]?UH%3\?30U45 M3Z^[!7862B#5X.H[>XUH\=)SV+H( \+6L76)MMY9Z-"-!EMO]J*6/^V"J^/J MH:J*J]?= KCZ;:/L1;O^- NFOA&5/[VH&54Q]>!-O;U8!J,.5V_ZTRZX^F:& MZFL[,:I855R][A; U3^LP+@^[D_#8.O8>JBJ8NMUMP K,!_&ZIQK5&8_G[DJ M&E4Q=4Q=C*FW.JVHZT_#8.OLEH:J*K9>=PNT%ZOKH,'7FU&3)9A-&]#&;]I] M7/ UUF78H,*'D[?NL]/L?56#=QQ/II?Q_.*#%_.*O&9P[;ZVS7_,IW=/^N%K M[G:?_S!*)O;%]>Q+-5N-YS^\M5F1#.+1O(^[QW_VTU;SVQ^_5;E04.@W6I%;7]TETGWM_X(K'+J!+8B5.[I<.07_B@.UWAR MJ*K"+IZ,)XLF62C2O#;J@JJSD_@RLK(QM7AMU05<:5(5LF MV2HSYF%7A,JD9H*V4+15IF;"K@B5L670%HHVM@R[H:JL9@VCO;=$RCQPBX!; M9M@5H3*9FZ M%&V5 MF9NP*T)E;!FTA:*-+<-NJ"JK6S8#I.57$#?Y0)Z'ZR> AXB M5-:3+K_56.)D(W1SU;$/@OIF%S*Q]4UE$C/A6B+7>#+LAJHRG@S7$KG&DV$W M5)5)EH=LF63CRK ;JLIJSL[@RLK(QI5A-U25U;CRUEZTZX_L,N'V:)]/9:X\ MV(I0F:1,T!:*MLJD3-@5H3*V#-I"T<:683=4E=6L8+0YJ*R-;96Y\K K0F4U MOMQC85D;V^SXP6ZH*JO*E>?F>6]SY==?G$!&KOS^X#_3)$_*'/EMDTP*>Y55 M"?/5)?29'<6%'3XU>;['7?,^>#_U.D2HK"=YGJ*ZRM!6.?&!71$JDZH)UQ*Y MQI-A-U25\62XEL@UG@R[H:I,^CQDRR0;5X;=4%560ATB5"9)'K2%HJUR>@.[(E0F(1.N M)7*-)\-NJ"KCR7 MD6L\&79#55E-DOQ6WZAJ@J[W#2_XA1Z1LS>IM!ST_QB"I\4US8S@VOWQ6S^U#SY/2Z;]\'D MJ=+(RKO%DV U593P9KB5RC2?#;J@JJ\F4 MWVIPU_RZ->:N>>%N(1-;WU16; 5H;(>3VXS3E;ER>ST@6V8*NO)CM]J1(V6/\++Q/N^*W.Y_(K%/8]_-_'P M7].\&+OOD)O,EI?)3ZY,D9KBVIID[%!R?Y]>FL*]-)V,WIMXG&9%\D=UZ;Q) M)N;L75+\8;-1/!D^-;>^V> 2>A]B!)4\1*A,#+LAJJRFN1Z7%D9V;@R[(:JLIHC-[BR,K)Q9=@-565< M&;)EDJTRO1YV1:BL)X\36U:&MLI,3M@5H3*V#-I"T<:683=4E=6L86PUN>]X MW1HOGLRY 4]6F& /MB)45N/)6+(ZMMGO@]U05=:39,\5]#70S17T*U;X7I)\ ME4F?V?)7GIPOW^0R>A_LGM(>(E0F7QZTA:*M&;)EDJ\R7 MAUT1*I.8"=I"T5:9F F[(E3&ED%;*-K8,NR&JK*:-8Q>U/5'==CF4OI0585= M?'F5=4PPYK5KS*7TPMU")K:^J:PG7[Z\E+[MC_ R\>92^C6*>U)$RM@R: M%&UN&W5!55K.&T8X:_J@.VUPS'ZJJ ML(LOKS([$V->N\:+I\RSWQ>D6\C$UC>5=:7,<\>\CRGSJRI/\" _WERDV=!F MM^H-T^G%R)I6Y%YHJF>YB3,GTWH4GRMZD8Z&BS7!U^J]GYO]*FW>#C=>#>)^ M7GNM:OMKWYLHO'$K?2E:GHZ2H9G]DOFF4?WWQ;:Y?8U *_JK/ZTTRY_?2$-) MB-3=7B_:J\G.FHM[F< ^4Y.]W9]&$4F())XUE4^1A#"RACUK0DCPOD8(J=^< M""&$$%DA9+?-1$23M1%%ZOBM1^LEJ^U$01HHB>*-):(E.2.!*\N1%'ZG-94Q)% XTA[IQ?M$DCTN!M[[/5;%($DA$ RJQ1#)%FP MY9K1[N+59G0$DF8][C:K0_-=$3L)W-\-D[>//V&S]? 1RS\^>*+G]YYG]Z9X M\'G+Z/;HFS8;G[SK[!M7WW_>KG]_UGAF!G8T*EO.,7#WYSD3U9_GN W<1]CL MCJTY&(-T-(IOU5DS:V_N$Z\\Z MT&-6,A-B95[R^1H_5?,] OG7$OWJY-2FW=@VK49S\72U5;77QLM9;4[X1ZQD@9)6*Q:W';6_(FWSP6L4 M#V!7VQB-Z"N&0:J:XBYBM.H-&+UH[ZF]QHN8\H66_-IF.TCSPJ27YB9+A]-! MD1OWU,-M8W\?C*:EF":9%/'D*BF'''&>V\+$XS0KDC_B(DDG6F/,&AJB9BOK MK.@:6VFQG=C1RFFV;*SNQ63RJW"L>CI-)DKMW*)*W M%@/SHC/Y9F#,&/TSNE[4_(J30"J,S@W/BFPZ**99N?15NEQ:7-O,-5U>F,R6 M*V1NZFB<[Q5)97LYTT@9?M9\>J? S_ SSYKM'U/W_8OWSKK&=IBP[B7(L)A! M8D3A--O^X#_3)$]* ]HNMQ3M55:Y437&RNPH7N;>*J:0.%BX7<%G!^MN M/]]L;[+TK7,P9UE;%W9B+Y/B6^-^R9G9(!U;4\2_USD9Q,'J<; ])HVA.EW[ M*ZISJ'"Z8UN8?IQ-G&ZYB8LB2RZFLS/G1>I>Y?QN4F1IM2-0#>4RF]>X?XFC MK789K/'4;H&C,7;SK-D>.%IZ:?Z9C,EOB$0 M?=\<:#8;0%5\79JO+Y1JH\'7FYU>U/.G9?!U?#U45?'UNEL 7__@Z\U.#5:MT MVLUH\S?#XNNLP(A3%5^ONP7P]0];I5%CUY^&46+K&[^0]W'!UUB;88,*'T[> MNL].L_=5B=YQ/)E>QO.+$5[,"_::P;7[VC;_,9_>/>F'K[G;??[#*)G8%]>S M+]5L-9[_\-9F13*(1_,^[A[_V4];S6]__,Z]Q4\;KW'RA2BM+TBOOV/H<**: M59Y5>M 09[>:S24VK\%[S1L=&S!EA5,GL!6A\BR?5X,KO_!'=-#&ED-5%7:Q M96PY((%]0QM;AMU059Y52<"605L]'BQ]"!6P3<*FL!P*X(E6?Y M_AJ,F?&R,K15)O/#K@B5]8R7.XR7M<'-0@;LAJJR'F-NN.&3/[HKH7OAA/KU M5S"0DE!?Q).KY&)D39SGMC#Q.,V*Y(^X2-+)4U/H6\NFT&^@T(V^R$HQ#Q$J MZTFA7WPE"K1%H*URP@.[(E36DZRYU>STN)=CW2I[5<,=6P;;,%768\N,EI6A MC2W#;J@JDT,/VD+1QI9A-U25R0H";:%HJ\RAAUT1*F/+H"T4;4;+L!NJRM@R M: M%&UN&W5!5UG/TO+43-?S1';HWX\P*D^AA5X3*)-&#ME"T52;1PZX(E?4, MF)O-/4XN:\.;M0S8#55E/=;O#S@!NX/4IA9#[8B5-9CRHR5E:'-6!EV0U496P9MH6ACR[ ;JLIZ M3J,WH[8_L@,WM].'JBKL Z>GD(<(E?7DS6^Y M7NJ/[C+IYNICX78A$UO?5"8]$[2%HHTMPVZH*F/+H"T4;6P9=D-5F:QYT!:* M-K8,NZ&J3"80: M%6V7>/.R*4%F/+6^UG!;^""\3;W;\A/N%3&Q]4UF/*S-8 M5H8VM@R[H:JLY[1YA\-QVN!6F38/NR)4)FT>M(6BK3)M'G9%J*QGO-SLL;:L MC6Y6,F W5)7U.',C:K"4X6W>_/H+%:Y$F9+[]MDDEAK[(J>;ZZ MF3ZSH[BPPZX@-X#ZZ=TAPB5]2324\A1&=HJYSVP*T)EM^*Z9KC^ZRZ1[\R*4)E\3- 6BC:V#+NAJHPM M@[90M+%EV U593UI\EN=%A<#^;,[BRL'Z1=D6H MC"V#ME"T&2W#;J@J8\N@+11M;!EV0U59SQ'S72[0U :WRCQYV!6A,GGRH"T4 M;95Y\K K0F4]X^5V9XD\>>@603OPPK=W#COI<+]:9;> MV'AB?IN4]\P?V6&9"6]>VK?)P)I3>S4=K22=?I=;YSVP?TIVB%"9='K0%HJV MRKD/[(I0F;Q-T!:*-K8,NZ&JK,>6MYK-J../\#+QIJJN<+^0B:UO*NO)IF>P MK QM;!EV0U69!"'0%HJVRG1ZV!6A,K8,VD+19K0,NZ&JC"V#ME"TL678#55E M/8?0N453'=PJT^EA5X3*I-.#ME"T5:;3PZX(E?6,E_>BMC^R S<+&:&J"KL8 M\VJSZ1M=?W170C?7SZ]8X9/BVF9F<.V^F,V?FC*_QPWT'G@\E3M$J$S*/&@+ M15OE! =V1:BL)S<36U:&-K8,NZ&JC"V#ME"TL678#55E/3GS6\W=:/'] /#F M!GH?!/7-+V1BZYO*) &!ME"T5:;,PZX(E;%ET!:*-J-EV U596P9M(6BC2W# M;J@JZSEIWHFXMDT9W"I3YF%7A,IZ4N8;W'2L#6Z52?.P*T)E/2/F9CO:]4=W MZ&8M(U1581=G7G'6_(X_NBNAFSOH5ZSPV;ND^,-FHW@R-$7\N\EL^2M/39]O M-KERW@.WIU:'")7)GP=MH6BKG.K K@B52=0$;:%H8\NP&ZK*V#)H"T4;6X;= M4%76DS^/+2M#&UN&W5!5)B4(M(6BK3*!'G9%J(PM@[90M!DMPVZH*F/+H"T4 M;6P9=D-56<^A\U9OF7P@\!:!M\H4>M@5H;*>%'I&S,K05IE #[LB5-8S8MYB MR+P!E1>_SH"%C" -0R:VOJFLR):;46OQ]'GP?K(K<]_\BL6=WS=OLR).)E7N M?#S\US0OQNX;/?G^^6:+"^@],'S*=HA0F01ZT!:*MLK9#NR*4)E,3= 6BC:V M#+NAJHPM@[90M+%EV U591+H05LHVM@R[(:J,BE!H"T4;94)]+ K0F5L&;2% MHLUH&79#51E;!FVA:&/+L!NJRGK.G3>CEC^R SJ*NQR SWCY8 $]@UM ME>GSL"M"93WCY2T&S&O7>/'D>18Q@K0+F=CZIK(B4VY$C:8_PLO$^ZN2YU=5 MJ.!!IKRY2+.AS6[5&Z;3BY$UKS\W M^U4"O1UNO"[$O0SW6L7VU[TW48'C5OI2M#P=)4,S^R7S3:/Z[XMM<_L:@4[T M5W]::99)OY&&DA"HNRWGX#6Y67-Q+Q/89VJRM_NS*"()D<2SIO(JDG2)).O8 M'B&*!&]M1)'Z_8DH0A01%T6:C7;4()+HL3120)(9+,RBL0219LN9U> M-UI\"XI($KR]$4GJ]R@B20B19);C1B1A9X^QNY'%^O,C,=S^5C[- !RF_<[-U\X4.4S743O?YXX_5;&SDN=[$5]8T M71>)?S+II6EURT?\K[_\>)U]Z 57]L5%9N-_OX@O"YM]'X_>Q>_S6\@;C2^6 M7[LO0RE+Z\^:\CXY?_EQ1DG%S+PO_?U9XYD9V-&H["VNW]W]>=X/JS_/N_C M?8+-[OKSO#,.TM$HOLGM][<__& ^>I;;NDGN!>Y3W!MU=I_5:OI[>\\?M>;9 M0Z[,FS]?/NE+-'XM>O\\/#KJGYJ?#T^.^N?F]65.^V].3L_[+\WYB=E_^=^_ MG94_G_;/?OOU_(R>0$^0VA->G9R:\]=]:Y2DDWS;V-\'UDT4;ZP; MBU^[B:*)Q^ET4KA_F4[BZ="1-UR\$C.]80V]H5:]>U%;8!?P<%44C;&.\$7N M19WE;N8!;_ .2F1 !N3P1>Y4QZGP:?"6*C(@ W+X(K>K^FOX-'A+%1F0 3E\ MD7O1 C)#-W2'*C(@ W+X(G>C=@>?!F^Y(@,R((> M M6V1 !N3P1>Y$NSU\&KSEB@S(@!R^R/@T>"LM+_11]=;/UMD5UPN6J/*%EOS: M9CM(\Z(L+'V3I^IA5=IN-"W%-,FDB"=725G@.Y MC;/!=54G>VC?VE%Z,W;?I?Z>\V)1Y5SQ<)Q,DMR]0Y&\M?7W(:[9 MA6?VB%OA5MTJ91:W^DRS[0_^,TWRI'2I[7)6:*^RRK*JT55F1W%AA_7W(NS+ M-_MBYNB?S;6QN<>:[:2:)R:303JV9LO^?F,GN?UVVTPLZUVX%J[%40H?F^U- MEKYU@S,W&MNZL!-[F13?&O=+MSY6Q+^SPJ7)OJ3Q[;,M=:MT0VSI,\UV; NS M]6N:Y]^:?IQ-G'QY>;+^G\EX[ 99/R?.FPKSVGV-\E^VS>%D$-7?J9A"XF:X M&6[V2;.]3$;3P@[-UJAR-'OK:#?5QN)X[$9?^;7SB/I[$A:V<"KJP:M7C5<' MZ\R)K[)3PY9W/S>G]B;-EEGB7;^P:U)U)F+T!1GK2];=A*A_ZOV;)U&S;10T1V ^="%&Q=WGVWEDL M0UF'O7]]UB74>I#B(JYRS/WSF*U$G28^^Y> MU/*G:?!VO#UD4?'VVM?<%RHQHCK>'+"K>7ON:#.<@/W@[R^TJ70A1 ML79YUMY9K$*$#FO?ZNRTHIX_C2/5W;_U2N+P]<38/6D(C-W/=MEJ12TV4C?J MZPO7[%E[$:PUUNSYLQ(]*]3VL-T,KMW7 MMOF/^?3N23]\S=WN\Q]&R<2^N)Y]J6:K\?R'MS8KDD$\FG=Q]_BNLS1=.[JW M^&GCI:^(TAL65:0+^:;SK *0DD#;B=K^*"^5\,7G3SASB(XAE5O?=)X5[]'A MS"_\D1V\\>:0107>C=QJ5.XYX\W@+1)OO!EX@]6Y*IV#-4.W2+JQ9N -5N=9 MW1N\&;Q%XHTW V^P.L_*UN#-X"T2;[P9>(/5>59V!F\&;Y%XX\W &ZS.L[(Q M>#-XB\0;;P;>8'5NX>'2*.LO1".D-$H13ZZ2 MBY$U<9[;PL3C-"N2/^(B22=/+8;26K88"B7+ BU9)M)W?--94S&4Q?<+P%L( MWG@S\ :KLZ9R*%L=[L3V:TD*;P[1,Z1RZYO.FO9R&3>KPQMO!MY@=:8<"G3+ MI1MK!MY@=:8<"G@+QAMO!MY@=:8<"G@+QAMO!MY@=:8<"G@+QAMO!MY@=:8< M"G@+QAMO!MY@=:8<"G@+QAMO!MY@==9TA&YG)^KZHSR$8\\ABPJ\&UG6T)-T MW^[ASPH1QY^!-UB=-?ESTTT5_%%>#>$+%T99?QD:$851?DG3X;MD-#+Q9&B2 MCZND)..;.,G&[ML]M49*>]D:*90?"[$LEAH?JOUZ96JD@+=8O/%FX U69TTU M4O!F=7CCS< ;K,Z:-GCQ9G5XX\W &ZS.U$B!;KET8\W &ZS.FFJD;/66*OL* MXU^I,S<1R?8,J=SZIC,U4L!;,-YX,_ &JS,U4L!;,-YX,_ &JS,U4L!;,-YX M,_ &JS,U4L!;,-YX,_ &J[.F(W3=:,>0105>['FEVC>B=L@O'&FX$W6)TUE4/!F]7AC3<#;[ Z:ZJ'LM7N1EP5MW:9%R]5A36':!E2 MN?5-9\JA@+=@O/%FX U69\JA@+=@O/%FX U69TTGZ':BMC_" SCN'+*HP+N1 M50T]Z?:MW26JH4"X$,*Q9^ -5F=-]MR(FHM70X'P51&^<#64]1>@$5$-97_P MGVF2)V45E&V33 I[E54E44P\&9K,CN+"#I]:'J6W;'D4:HZ%6 M+C0?5?J^R MGO(H5%-7AS?>#+S!ZDQQ%/ 6C#?>#+S!ZJQI:Q=O5HI,<13HEDLW MU@R\P>I,<13P%HPWW@R\P>I,<13P%HPWW@R\P>JLJ3@*WJP.;[P9>(/565-U ME*UFEUOOUR_SXH6KL.80+4,JM[[I3'$4\!:,-]X,O,'JK.D$76N):J\ +@1P MW!EX@]594_9]LQ7M^J,\A&//(8L*O-CSBHNC-'K^**^&\(6+HZR_'HV(XBB_ M)D5R595#>6H)E)UE2Z!0:"S$ EAJG*;VNY0I@0+>8O'&FX$W6)TI@0+>@O'& MFX$W6)TU;>#BS>KPQIN!-UB=%95 V6HV&A'5T]>N,Y^Z:RH0@JC9G5T8\W &ZS.5$@!;\%X MX\W &ZS.5$@!;\%XX\W &ZS.5$@!;\%XX\W &ZS.5$@!;\%XX\W &ZS.5$@! M;\%XX\W &ZS.FD[0M:.6/\(#..X/\A"./8%?*?/B!:IPYA =0RJWONE,%13P%HPWW@R\P>I,%13P%HPW MW@R\P>I,%13P%HPWW@R\P>I,%13P%HPWW@R\P>JLJ0K*5K,5=?V17BKB; 7* MM@RIW/JFLZ8#=#M+9-D#N!# <6?@#59G35GV6ZVH[8_R4@EGW"S;,:1RZYO. MJIRY$34XW;Q1:UZX]LGZR\V(J'UR'O]NXN&_IGDQ=M\A-YD=Q85[7E.DIKBV M)AD[EMS?IY>F<"]-)Z/W)AZG69'\X5Z73DPR,6?ODN(/FXWBR?"IU5.:C67+ MIU"-+,0J65*MRC>=*9\"WH+QQIN!-UB=*9\"WH+QQIN!-UB=->W^XLWJ\,:; M@3=8G1653\&:U=&--0-OL#I3/P6\!>.--P-OL#I3/P6\!>.--P-OL#I3/P6\ M!>.--P-OL#I3/P6\!>.--P-OL#IKJI^"-ZO#&V\&WF!UUG2$;KEK;D!\!8F@ M]4LBQN*U!R%\580O7$9E_45K M1)11N5<"I:J3DMGR5YY<#:6Y;#44:I.%6#-+C>W4?O$RU5# 6RS>>#/P!JLS MU5# 6S#>>#/P!JNSIJU*^'UK7K@.ROI+SXBH@W)27-O,#&Q6Q,FDJH02#_\US8NQ M^T;YD\NAM)8MAT*=L1#K7TDU'M]TIAP*> O&&V\&WF!UIAP*> O&&V\&WF!U MUK27BS>KPQMO!MY@=:8<"G3+I1MK!MY@=:8<"G@+QAMO!MY@=:8<"G@+QAMO M!MY@=:8<"G@+QAMO!MY@=:8<"G@+QAMO!MY@=:8<"G@+QAMO!MY@==9TA*X7 M-?T1'L!QYY!%!=Z-K&HH2KK'GC>@\N+E4'#F$!U#*K>^Z:S*F99ZI'N8DSIU/P-5+ZEY=V4)CTT@R3 MT;1(WEJ37[M'RTVMFK*BAO7BY;U,UYLHH;3 ME\3_IE'])]/8?&N+6;F5532'C/B^^1+N2QL2_8)H$)[21(, VF)6X(5H0#10 MV2^(!K4[$-' G[:8[8?3')Z;$.(3 <)3F@@00%M4A6N8#C =4-DM" :U&Q#! MP)^VF)7*(1H0#53V"Z)![0Y$-/"G+6;%>8@&1 .5_8)H4+L#$0W\:8M9.2"B M =% 9;\@&M3N0$0#?]IB5H"(YO#TD2 -JBM;((P'R :!! M\ MK=S[N=D?_FN:%W:X\8IJCP&_6:E]=OY-U*Z[%;^4[;.>_Z76$1VF_^I/.STL M$;76II(1PIO;G9U>M.N_IXGL.379' &E=J,BH(014!Y6F2*@>'B1$J&$4*) M:4))X*'DX#QY&')+ (**UV>ZDXH$:XTH23P4/*PWA:AA%#BJ>Z$ M$N%*$TH"#R4/BW412@@EGNI.*!&N-*$D\%#RL-(7H810XJGNA!+A2A-* @\E M+4+)UVQ3A)(QP\K!( M#>'D3]MNI]-@=J++Y @GM=L4X81P(C*;O4$SYXH.?W'F?WIGCP<2&]Z4R$2I(Y*G]_UGAF!G8T*F%P6-W]>8Y9 M]>*;W'Y_^\,/9LYCPWV;9_=*T[D7N$]Q;]39?59K M)<>]O<7J.#[F3S,A5F90GR]CUVP\WF^^MI.\.CDUYZ_[YOCPN&^.3H[/7Y^9 M_O'+_DMSUG]SWC_ZN7]JVHUMTVHT%Q\3K[RRXZ;<:7.Z/V)."]1L7+&XW:CU M%:N-=13\]7%8O+8:IC3$9QKB+ERTZHT6O6CO*\; _@64+[3DUS;;09H7)KTT M-UDZG Z*W+BG'FX;^_M@-"W%-,FDB"=723G>B//<%B8>IUF1_!$723K1&F'6 MT! RC4Q #_'9V#K1SE>)R?@F3K)ZQV:X%JZ%:_6B'F.S M1Z>3138=%-.L7*,O!V9I<6TSUW1Y83);+N4GZ<2XH5J15".U'#,38F91>V=.:.OHR]IV/OL5MVHPV&(SS?; M_N _TR1/2I?:+@\^V*NLLJQJ@)794;S,[;'8EQK[8O+HG\TQ*'NTV=YDZ5MG M<\[7MB[LQ%XFQ;?&_9)SO$$ZMJ:(?V>Z*,:^ONK^2QS, P=CH/9HLQW;PM@X MFSC=I,47J7NSL;%)D:;6+60WG,INSJ"_&V%@'P[!" M:;;2L+9^K7RJ?^M;Z:7Y9S(>V\S\G+AQ5V%>NZ]1_LNV.9P,HOKG.TPT?9MH M2NL6N%F0S?8R&4T+.[P=>=V-Q&ZJ'CJ>'*BF>7G/AX(4RXS68>FN[TVM&FZ\*C*W7K3*28NNR M;)WUE[M6V6E$37\:!D_'TT.5%$^O>:MTH4()&CR]N1,U_&D8/'TC*E='P5$5 M6Y=EZZW%4A@UV'JOS5!=H0$A*9XNR],[BV45:/#TW:CK3[M@Z5AZJ))BZ0S3 M_6B5K>9>&U=?M\K?>B1P55XD=$'Q="^:P2-/9YC^P=,;T:X_#8.CLYB.HX?2 M##BZCZVRVVR0=Z30@9 44\?4A9IZ.]IK^],P2CQ]X>(Z:Z]6M<[B.AM4^'#R MUGUVFKVO2JZ/X\GT,I[? M?:EFJ_'\A[/D5+.I(@G5\G%R)HXSVUAXG&:%#+A!JDP%$] 6 MBK;*@^:P*T)E/9F9V+(RM!DJ VZ0*NLY98XG*T,;3P;<(%76,T[>[48-?W2' M[LVL8"BL8 *[(E1FM S:0M%F81EV0U59CRVWNTVR1[3AS4(&X :ILAY?;D8[ M37]T5T+WPB5,UE\S1F@)DV1\$R?9V'VAIQ8P:2];P(3"8.&5K%+B.[7?ST8! M$] 6B3:>#+A!JDP6$&@+11M/!MP@5:: "63+)!M+!MP@5:: "6@+11M/!MP@ M5=:S=+&UTX@6WZ4%[S677L62PS,+F1E8LO* MT&:H#+A!JJSGB#F>K QM/!EP@U19SSBY&W7]D1VX-[. H;!\">R*4)G!,F@+ M19MU9=@-564]MMSK1#U_=(=NEC%"E11PL>65*=^(VIR+\[9ZR?K+QO- 4=V<& MZ1U"VUPJRQJ M KLB5&:P#-I"T69=&79#55F/+3?;#)BUT6VY$C<5K34'WAHN: MK+^*C(RB)O^8.@V+]R:S8SLLRY:DDZ=6+>DN6[6$$F'A%:]2XC>U7]2FI6K) M5I-2Y^O6F*LS)7N%3&9]4YG$'] 6BC:>#+A!JKQ0S1)TAN905$92P U/9>J4 M@+90M/%DP U2998K0%LHVG@RX :ILIXZ)7BR,K15'BB'71$JZTG W.JU(^YC MX[!%0&KZ9A8RF?5-93V'R1DI*T,;3P;<(%76,TQN=J(]?W2'[LTL8"@L5 *[ M(E1FM S:0M%F71EV0U59CRUW]J(=?W2';M8Q0I44<+'E%18J:77\T5T)W0L7 M*EE_91@9A4KV!_^9)GE2%BC9-LFDL%=95:W$Q).AR>PH+NSPJ95+>LM6+J$. M6'@5JI084.V7L6FI7$+57&5HX\F &Z3*) .!ME"T\63 #5+EA6J78,F0'1S9 M6#+@!JDR=4Q 6RC:>#+@!JDR2Q>@+11M/!EP@U29.B:@+11ME>?-85>$RGH2 M-+%E96@S5 ;<(%76<]A\:W>)>[R@>\VEI7#D\+Q")K.^J:QGE-S"D+7!K;** M">R*4%G/4)GE"V5HLZH,NZ&JK,>6>U'#']F!FU6,4"4%7%QYA45,&FU_=%=" M]\)%3-9?-49&$9-?DR*YJLJ6/+54RC2HE-E/[?6R4*@%MD6CC MR8 ;I,KD^X"V4+3Q9, -4F5*E4"V3+*Q9, -4F4]I4JV.KM+[,N"-W<6UZZF M;V8ADUG?5&;E K2%HHTG VZ0*E.I!+2%HJWR3#GLBE!93PXFMJP,;8;*@!ND MRGI.E./)RM#&DP$W2)7UC)-WHCU_9 ?NS2Q@**Q5 KLB5&:P#-I"T69=&79# M55F/+7<:4=,?W:&;98Q0)05<;'F%Q4J:K&-X6ZQD_=5AI!4K,;DMBI$=NZ]B MKN+DR<5+FIUEJY=0 BR\XE1*?*?V6]BH7@+:(M'&DP$W2)7) 0)MH6CCR8 ; MI,I4+X%LF61CR8 ;I,IZJI>TVES"IHUN;!EP@U29U0O0%HHVG@RX0:I,!1/0 M%HJVRI/FL"M"93V9F=BR,K09*@-ND"KK.6:.)RM#&T\&W"!5UC-.WNI&+7]T METGWXM<4;&#Q0F'U$K 5H3(#9= 6BC9KRK ;JLIZ;'FKN1NU_1%>)MX^#9:Q M9)@-465%EMR(&HN7+@'O)UORPE5+UE\F1D;5DOXT2V]L/#&_3R2J;_^*8R)4Q 6RC:>#+@!JDR M24"@+11M/!EP@U1930F3; S@R.%YA4QF?5-93P431LG*T,:3 3=( ME5FY &VA:./)@!NDRI0O 6VA:*L\:@Z[(E36DY:)+2M#FZ$RX :ILIZSYGBR M,K3Q9, -4F4]X^3V$M5+@%L$W"I+F,"N")49+(.V4+195X;=4%768\O-3K1X MNCQTBZ";90S #5)E/;;LO5** <67J$J)4Y3^V5LU"L!;9%HX\F &Z3*9/V ME"T\63 #5)E/?5* M.M0Q7[?&U#&7;!4RF?5-93WE2K9V=J-=?X27B3>6+-DL9#+KF\JL6X"V4+3Q M9, -4F6JE8"V4+15GBJ'71$JZ\G"Q):5H#+@!JFR MGG%R>6KFD MV5RV= DEP,(K3J7$#+A!JJRF= F6 MK(QL+!EP@U193_$2/%D9VG@RX :I,DL7H"T4;3P9<(-4F>HEH"T4;95'S&%7 MA,IZLC*Q965H,U0&W"!5UG.^'$]6AC:>#+A!JJQGG-SJM9(O!66;X$ M=D6HS' 9M(6BS5*5X"VD+1QI,!-TB5R0 ";:%HX\F &Z3*%"^!;)ED8\F M&Z3*%"\!;:%HX\F &Z3*+%V ME"T\63 #5)EBI> ME"T51XQAUT1*NM)RL26 ME:'-4!EP@U19SQ%S/%D9VG@RX :ILIYQ?TB+UZZA#6,\,Q")K.^J:S(DAM1 TOVL73)JLK$ M/*A38B[2;&BS6_6&Z?1B9$TKS\U^ M5;[$#C=>E>>.XUJE]M>[-U']Z%;Z4K0\'25#,_LE\TVC^N^+;7/[&H$^]%=_ M6FE6QV0C#24A3#>W>ZUFU/+?S03VFIH,CD!"(/&UJ3P*)+,,)@*)MU7="2&$ M$.$Z$T("#R%[1)"%&Z[=Z-90?YXH0A01KC-1).@H,BMO0QA9].:_[79W-VK[ M[V8">PV!1+3.!)*@ PDK6JQH>:\Z(42TSH20H$/(K(00(800XK'J]8:0*F&$ M*$(4\:RI/(HBLTQNH@A1Q&/5F8B(UID0$G0(F272$$(((1ZK3@@1K3,A).@0 MPBQDN7WU-KOJJNSM?ETJ(@F1Q+.F\BB2,!E9JN4:49IWZ&((\01 M<7&DN=WL,"=197 L;1%(?&TJ DFH@:0;=7?\M[*-=IEF/>XV*V+V71$["=S? M#9.W2SWA@P=Z?N]Q=F^*!Q^W ,#E>S9;-U\ NA)RI_O\\8]M-C8BXYOXRIKF M[H_?Q3^9]-*TJNGU?_WEQ^OL Z57]L5%9N-_OX@O"YM]'X_>Q>_S6P@;C64* M:K8^DJ 3-7>^(,*GVKMF-?,.5KY!^>Y*X3W[IF^1R?=K/E>MG#!U]_ MX_]8_OWMM]OXA^?3F\]\MNL3HV1B7US//JG9OG;/WW>A*N7+MT$*WO*1U2\Q_8359A)<#AYZ[I.FKTW\61HQO%D M>AD/BFE6AHW,CN+"#LW@VCVHS4TR&8RF0VOL[P.;Y]4OI!3J9V]87%MLWOO M]J??*IIU\=G_'TZ,^WTS*9]_[-[VVMS8+$F'QGV:^Y4S>U/8\87[@'9CV[0: MS;WM93[*N4>>WJHP-+'Y:ZL1[1K71*.D?-KJ5>6_3[/,5D_G/&^<3-Q[N!=G M\3OW]NYO7%L:)_W-R'WD56;MV'U^=,=@%8R^/A;AD#CD"ARRA4/>.N3_5897 M&9^SK7ARE90](LYS6YAXG+I?^R,NROY_F:5CDTXS]_TF+W[9WW]C+EW?GPS* M_CZV<3[-G(5VM"6:3>%3Z@'LWYZCE+SO#*I_;_9[[D"OGGGDQ_WN; M.>],BNMTZD;HUTG^X-,?V.!+9Z;.?4K!TFEN1O:M'>7E&"T>_&>:Y$GY"]6O M3ZX^O/?VGSS>()Z4[_C>Y$Z@Y-*)-2G<5Z^>>I".;^+)^_)#YS^NQ=!VHW8; M0\/0OL+0VAC:AR%?-4BZ3#)G+?^9QIFSH6H"UVBY49$SILP.4M?%_W!CF*LT M';YSXQN3N%Z=9.50Y<, []+\M;/3B!IW(Z!R!/779J=U[Z]NAU#.&4JGZ1_U M]ZN7O73OY'PQLS>EQ3@?FDZ2PGF0\\@;.R@2YUCO/S>TR]UW<[\^_]KY[?>N MWG,VH'OX ']MMS_^@NXK-V__YN$';I=OYYK7C5>K$:[[-QMG@^OJ]X:EBZ8W ME01;?_MFM]5J_'#XYO1O\=@9;O7GY@_??NJA'X1[,"2^^\UR#F1Q M3]S3(_?LX)[WW/.E'W;B>_=8.MROW MJ,9[;N!5FJ'[&S.Q[\S5*+VH/# OLNE\SEG:P546CYW9Q<7M7#,OIX\VS:[B MR>UHS'W4O^U[6/Y#/'"]U;W:34^'=N#&A6[<.H[_77Z+\LTNTX$;/):F^_"3R_E\DF;N M8=RGEE/XS)FGN9?:OJ#>>ZN#=Y.,/^\U=7&EW' M[M/+;WF5.C&=+M5KRT^N2]G.KOMF0.:_XNS2?D[O]JB'-@F>3YU MX\"+]Y4#_!:=1>X7TN%L$)I-K\S^<.P\Q3G5S-YNAW:O7N[?#>HN74]*WU5? MQ!G*36;?5O/J#]^J&H>6<!Z_,\?.>J_-@1O@N9==NJX[2@HWNIS/N"M; M&\?EUWLXZCLO9_5N:%N^VMG8V Z3V9>ZCLO!J)N[E^N*TYGKVK>I,^Y[D_%[ MRPU.-_=M!O.HX-[4-:R3IEQLS4#W%\H'E31C/50W-DG=^[ASK?N7!K$O77$:MG07LW=<]:K9P91 M+5Y6?W/G'VX47 W7Y@NJP\763-W_G,O%>P-SXRQC4NX0%\E5//.5#[O& M\44U@'KPKX-T/+99910?_OK>)/-N\^/#/WYNR/5_Y8#F;>)FXY^^<.8W3O1K M-W::#[/D^+V+]QXZG85<38VFVW\ND>]G'M=.20JAU*CM)JLN^'8 MS!ZKQ=5RH2 I)[S3V=9W7BT@E'L];AAE+Z>C35*MGB99M7@;#\I=Z-PU4K[MGM&-*^UD,-O__C"<'-C;-=OTIEPC*!]@ M9L0?CUGM?>GNMLHGMP%@.:^??='Y +4::^?NJ>UM5"F_TZ=OID3XA,"JV?X/&;WQL!Q]9([S#3&'58OL=5G VK47+UQ(\]U;89SK;SRE>5NVLC^_ML M[>6N'U5?=/9LE\EHUK'NOL2PG-LDU2,^',OG>3JHUJ-FI+E_S.V=E&4_O3^W M6(B%DXJ:AT#,92EG,!?63I;'(78M4QK*=!1G[*YS+! M#DC*X-6?9L[57*#\;5+ZU9$=EJ\U+]VHP+G9J;URQC-;>1[?I*7'W+?%>Q[D M0I63Y-_EL0EGQ^ZEQ?R/\X6;:MGCD]!9[@-D=Y^1WPT%XMDA[.K-;Y=KIF[ M,3)'\?MRR[-9K>E41\W*:)7.^F$TM)#_EU_Z_MCG=A/C MPQ$[9^S.QI+\>KXS,)K%R*0:P=P&M@<2?[0E_><2?M)HGWZCF\Q%E\S1>K=Y MX13+AB_*T/7^=IVL?.J)+1>XRB&9^_CJ%&#U1O.AW^Q T(?E.S8I6 ;S*73L ML0QV;RY;S3+NO.CAM/-N1%K9W-UTHQQI%M4P]?;8QVP3\]U\8%GNS%Z[CW=& M4CU7V>?(S5_< MR+NTN' M\_GRQ\/YRS@IM1ZYF5$Z&X27X:QX/Y\^5U'-S1+*%4SB+$ M^_+SJP!1_MM+>VFK9GR3N2 _F#W'_NWQ[+M=H9=O/NP*W067:E/IJMQXGU0O MOK]#,@^D+JC:]]W#WTZZ9A.Z\GO]G*3C^4CB]BW* MHTGNZ^?3"X=)XN#XJ+E^FU3;^N[[N"]9'8-Z5\Z&W>M+SBI&W#?,2[;+W;"X MW$H?VAM;A8#[0=--9I,BS=Q;7">#Z]L_YM?)3=E<'G2M-M7*8Q4[Y?>]J":OX\01,)^C MNC'6OQPX@Q)+\\I>9-,RDE:CH5*J^]'ZAN[?[AJ;!*EWA^UL#]JWN'X@^;C9SK,$? M0[SR$+(K[SSD7C=U8XEJ'%/ZQ2L[+ ]I5F,_YP[WC<"]+,;P_NE+\[&P;:2;GK M,[P=?E2K$P\/_Y='63_XU/VW<]_TOOO-9QO#VQ&SL[QRB>C*3FZG'^7QUJ*R MP@OWEY<)Z8WLR?OE44_);Q2V*7\R.V4]]Y#/#G4>9!/>'2(L7SI?![[W&U_7 MU5LWGVPHZ.K8[&VMIF.O/L\OV([],AE-RY"?7\?5OG6Y!C/-YVLW58=U/]^^ MJ/_F[/L%>ZZ8TC5[JR]=\_G8L(K9U==XVASW07F")GOV9(>KHZ98KQ5U=Y$?NWZYSTR^WI_VIE-?\W+!@/9!O3N]'RJIMT$4>6,9'!>X> ME"+<3*W.#04S_ZWE2TUQ6_%1G/U\7&RJU:BOV"-F(V3(4K>O^%X$>+/52G6V M0[M[W]-I"AWCR%IE7MC<#UZ]:KPZP-S_5.('BT/YPD2O75\M1-M.N/\EH 9_*_.1\O3P7,C+P\:#@=SQ(-"F-GI5 6M_=-CN&_M!B@ MHH=X-8Q_2FN("!/-J./-91R/VI6*?K'QP?Z7(D<-5SQM2/>[+>"AOU.!\"Y] M\C.8;&@^(>#JIXU-2G:CUL:;C\N?5G_YD_93\YQ(746!9V(O7Q O7S M^NZY+8HJ;?"V:$\RN2S39&:YFJ/X73Y-RI3Z8I;L.G9N5T"Q39JNLP;R<=(^2 M09GE>U?#I_HV=51W6<&;5I%O1>_JO"?-OO\FGA;IYF/KCQ>9^>XGH??ME:<( M-G/?WK*PU'M&\>[ 2[-;[XF7O3V!1^G^>7ATU#\U/Q^>'/7/S>N37U\>'O]R MMFT.CP\B?U:T-!YT@?MUBG_:/S@Y/CC\]7#__/#DV)R\,L>._X/]L]?FS>G) M_QZ^[+\T/_\_<_*F?^I>[J5R_^KD]&_?-'N-'\Y?]V]_/Y71R?'YZ_/ M9C_WC\L(<=9_<]X_^KD_?Y_;X\!W=Y;1>^@]4GO/5EF*>';77KYMII-X.G1\ M#;^%^3J9KU/O3B-J?)QN%N(6CF_G.;0<+*M;9G0&9SDRMW!BT U49G0&9SDR MMZ./YW^H"KRAR(S.X"Q'9D;%H!NJS.@,SBP= M[L#-<#E$3;6,+^J6&9W!68[,+"(#;[@RHS,XRY&943'HABHS.H-SR(O(#U:, MU10#_.)- +UZLQM:.TKO 3B_SNS#>TC,W=4 =PE!7 T0_.KHO0DXAH/A>'3O MD5=^XUNI2TTY6?Z,BNJ-!K['<5V2H#'14RG7,V3"CSSM/[64 M:<"/UCA'PT@P$G4#&R9?W@Z \"/\2-W !C_R\(I#*7D6Q[8P@SB_-C=9^C8I MUT$OWIOTQF9QX9[;Q(,B>9L426A7GDC<,/ZK1TVPBC:X%QG"O:.DO=N,VAXU MC)*S$C7+K/#4&K:.K>NQ]>[.3K3XD!];EV%!PKK!^^M4]N@V&87#<:@5(K,:4][K1#L>Z2X3 M;X],6>7B-]P*D5F-+;=:K6C7(^%E\NV1+S-8AMI09=;CRNT]EC VZLH;/PKN M3UV VE:CT^+:9N5)\1N;%>^WS+=5 MO**VD!$KVHVHM_&V\3:;R,]1_6IE;RD*&-YY#V' FZ8@#-P+ ]U=PH"N,$#9 M0P(!34$@^"@0[.XML:!/(! 0")@/$ 9H"L+ @S#0['9KJ"1 '/C:?85-U!L> MIM.+D36M2%Q8>%76^Z\*SUR.TG=>[9PM6P/K02-)CA^+9SYM9&=Y(^TD(K:T M=G>BEC<%S!XU-8E]QI>2BN(#BG=G7P@D!!)I@:33ZBRQ:4$@"=_?'M^Y()00 M2NIO*T))J*&DUZLACX%04G2>NQMMG?R M71$["=S?#9.W2SWA@P=Z_C%)]S_O">\Z2$=I]OTW\;1(-\_JCQ>9^>ZGCY[@ ML5Y8/D"S=?.%7EFQL--]_B?*K?^YWL17COGFC]_%/YGTTK2J5*C_^LN/U]F' MCG9E7UQD-O[WB_BRL-GW\>A=_#Z_[4>-QBS+<89,!="\8_W]6>.9&=A1>4?* MP'7"NS_/.V7UYWE_GUTPYYSW3M?@HOLGM][<__& ^^M3;W;Z[FUB:NS5? MQ7+[S41=H_+/PZ.C_JGY^?#DJ']N7I_\^O+P^)>S;7-X?! ]N@-+FZRU34[[ M!R?'!X>_'NZ?'YX&S.3\S^ MR__^[>R\_W+V*AJMGD;[3./0%/4TQ:N3T]E]X>>O^[<_G/;G/^X?OYS]<'QX M//^KHY/C\]=GLY_[QR]=3SKKOSGO'_W2 MB7'O-2J37[?-=!)/AVX$/ZSUK-"C3=!NR2A^Z>&*B<3%#N]D=O/E%E)#M!B9 M6U$'/X;>4&5N1MT.4D.T&)E;4;N''Q/FPI 54]C4M*-)F(-H.3+CQ] ;L,S- MJ+>+U! M1N96U-J5Z,?L?$@G=X,&L;D]/>]$7FS?0\)VJG?2PS?3D4!E9?#& M+H@PJ9&979" 927,80K!RLPN"$2+DAD_AMZ 9687!*)%RW*?67K6"OT@9:W%+^N?791'?(_>/U[GIN^\Q-&?VIK#C"YO=);/5 M5YF!Y?V5*CI;.U)M.AO46NP$QB/C+@MJ*8C%)2E)K!Z,5;?Z3P1=-FQP"=7:E6'2W"ES[O2@[HW MN%+8KL2AD]4Z.\9=[W"RB7%[.9ST[0Y#-0:_T+ 35UKO<+*WBROY.)S$E5CW M]'G=<^WW/$M)T3RVA3F+1S;WZ KM!2Q?X@FGQ6_K6'\3M!9;7E9Q&4=S>Z^U M5\,UYISPJU=FP0<6L'?=]MY<;)U>B;WO[KFN[E'K8.^;L7>-2_A$S3!E)6K6 MWP2MQ39)5$3-SO9>>R]J>=0Z1$WL/5A9L??ZFZ"YV&Z3"GOO;N]V>U'7H];! MWC=C[V2UKG=36\K&T4&:%^6]N#=9.IP.BMPXLQQN&_O[8#0MG]PDDR*>7"7E MK;=QGMO"Q.,T*Y(_XB)))_[D<6,LGE8%#3AX]O:66$^$K M"RK#G]O=:,IS2' MC,#;V5MB17"U;N5A-JV"KD$)$A]LB(C@35,\3 DB(G1Z48^(H*AK4!&]*AUL'>2H *6E:A)U!09-2EZ]Z%=VMN-9IM)D3H?PMZQ M=Z'V3M&[^_:^TUFFIBGV+L.'U*=?L7<4*+D8A$_%ZY :H@.1F1D-] 8L\V+% MZI :H@.1F7T9PEPXLF(*/A6G0VJ(#D1F_!AZ Y9YL5)T2 W1@GV7L33X9F'$^FE_&@F&;E0V=V%!=V: ;7[GO;W*,D2EQD@]7D M5)P1:$5MCX2';^X\#596Z-UD93<5[ES.T#Q2'L W8\\:]TZ(>F'*BBELLJ*: MBJC784ZBCF_<&7H#EEG1I3Z=G1JN%@#PNNU9^<8**24+2OR/J1.Q>&\R.[;# M9+DK>]B&E;$-JVD#A:)B^OC6.5F!7B$R*]I :42['@D/W^2>!"PK00]3"%9F M1?LG6U3"7+_(W_JC,,X,N '+K&COQ,V\/!(>OLE)"2@GY<$^B9H;= XG13RY M2BY&UL1Y;@L3C].L2/Y8;F>%J]:\,9Q-I:]PU=IMT.WLU7!B@:O6ZNL:7+[I M@PT1$;QIBH=7Q1 1_G][U_NF_\-.TG2<&9M( F,[3C/CV"3AF1A2 MF[[S3K^MT1JK%8A*PGFI.0%QGF/C'JL59>KN9KVIY_RE5_ A7W]0X"@.G(J> M@GEDI4?77TQ[X@B&8H>A+*=R,)0\AK)7P:/M,)3J#>6>X Z& O.V%FN8M^7F MO1SJP;R?JEU]LX'5(#.1@Z&8H%0P%"L,93D3A*$\&1IN>O7M%7:*A:'8+W*/ MQ(:,# 6;%A*A MBV'.=P85H :C+8&9??*Q]DT\J20?GZ:;XLV^F$%;I$(F2CPKBD7#:-.KX!@H M$+Q:F(FL2\0K"09V*.!^:6>6(1#VEN0)K9$9Q(7K(DS>@2*1K>]NA2?W@47PDY M\L50CB;GLI].XNRB8Q7*[)"A_H7^WBHQ)PJ$@IC42D+"(IT*3F$ OZM^HH#$ MXL4T6,%>DQI+B*ASTR#@P6^TF5@,*TP/HF MS(P"%2Q)^/$;Z@SV6@PSHTS% MJ>T:!#SXC184M*"8 _'O$PUB>B5B-51^(-,@0B>*86J!3I0"L=\R"':P&T]^ M60LKV(M6%&BS90B;QFZ>T0DLSTY8(0KH18'E68:P:>R&-H.]%L/,*#B!-G-C M-_O8I*A@:BDCN3[U:(YA$H6!+V9_**87-):Q!LM^W-NC5(X&07:LDTP2E0HY MC.(T^+Y:JE)&!OM827 6566'W/^;RML MQ0/OM7]@P ],$"'X@3&EF$5=\(.;M=@V_(#1P%B,Q/CZ0>D=1X]%9WXTR<(E MKT8.]P/_KTF2;>$V,/5(G.M29"#>:P*/U0J^77HW4RGUHF'LJVQ:5*S,W77V M!R4.0Z=@[.]=Z=%U&,-VSH:=F#4F\D9RL),G[40+"^R$T=!Y)+2#G<"VK>0T MK)M"K983/5AWCI5@_IW\8-WV#QV6EH*5H!UU,LY.E@-!V$F.E6 ==L)HZ#P2 M&3*QDUE<^":5^F+US_S@O9;&N_^)=^U$8Q6]?RDD:E8_6N[-8 MO'E_ZPH>4KOL EQO_(CZ38FPL_WJ">36?UU?Y4"SVWOW1KX7T;GPIL]*_/S3 MNXOXQZ@:J*VS6,F_M^1YJN*W,OPFKY)KP7*<53M/2R'+H^\ZH_>4[//A_ML+ MYX7HJS#,]%2KP\V_YVHQ_?= M^-S]W!!R10D[76Y*1UV.T/W9-?7[I-9[_WN77]XJ0U?WG0.9J]Z+0[\Q\==SN]SZ>SUZW.D2[K:>MK MKW7\H35_G[JS*3S'^7F[XKTT] M*]2EN/]%U4\28_>6LC93R+%O'* &HRV!F>?VJ& O$9C=VG834(/19&"&'@-6 M>V"%*)1E+/2B$J<9!#W[#_2R%%7,WA"#$H ;,T&/ "E@A"@A!"$,-F!&" M6 LKV(L0A!C4@!GS8XM"D,7$@^^^SHN=3\UJ&Y^\O5HCYT;SY.[H]RYBI<2Q M_N5%(EKZ>_CB5(U3-3Q3\4TG6W7;SN/N?J&(XF"OLK$FB:%!PNT]P6>RPMT) M1M!MZ#8/W>8[1Z^6X#="[U6\-4']67N \W"";)L)*#U)I7\6T6E;@4FJY$T? M+8$JW:]*;H5'AT.5L)8U$D,(MQG"O?.,C82Y"'>5TTG3SAEE(_"-/.LKJ-)Z M%[G.,\Y-Y*)*54XGH4J8,IE\VW/M1R\0Z<_LCE4L4WV%8AQ'YT$J-L(H25[G MIK<1QY%0?-CI%X-*X.6[U\SB!!%O;Z_F&50;/.I7!LP\;_= W!F(NYOOECT/ M<6]LUW8-J@W$'>(.6 $K/-,TS\R5EK#PS(VZMUO;-J@X-$W3H%LR//M0(>P, MA-W+%SBQ$/9=1U^U0;6AJ>NFJ1#563MV]BP8X?;H4G]X%%]-#_0;RM'D7/;3 M29Q=_*;!;ZHF"?:R@#G?!J D MU%E?:],@Y$%PR#-@!:P0A2I<+\]^H"1UG S"E+:317"%/ U: M_OV_P' :#.<9IX"]1&#F%*?4F[7\.Z&!X3083G7^C#Z5@A'^%$7^MR ,IVTJ MP>UP)1B.91 /]=S&\P;6P@KVHD4%VFP9PJ:Q&]H, M6.V!%:* _I2"L6^N%*F X308SC-2 7N)P,PH4MEQ:JY!R(/@F#ZC0\48A$]4 MDL:3^5Y?TU@E2B]4+/I1DHI8^?I70302P2A( YD&ERML (9TED8ZRRE;<9LX M$(8=P:F:)=C+ F9&\T;'2L$(_S[1&*97(E9#Y0>K[?N%,)9&&,LJ0''P,!@[ M@E-U0["7!%X7Q"QE 3.C1&7#PSDJ:P?YM3D(0YD!JSVP M$M4#XV!F%*:XVSC8D1W!>88I8"\1F!F%*;LK/. %?M/@-]7),[I1"D;X2Y & M S2A&*@1:$(I59AK!I[.:9GX"]1&!FE)]L>'6TGJP=973"FY.=H.LD'\*M21R-E1R) M/T99?G*L_* O0W&D+H.^$B=J, G1DV*@/:(GI#:7&\$ASX#5'E@A"FA)*=KU5ME:& 2G07">B0K82P1F1HF*NPMY9D=P MJK/GTCM2%B,4<1;%OHJO(4RB,/#%[._$]'K&,M98V0][-[U0L>A?Z&^F$G.B MPB=*\-*9_@=]*:][I8ARD#!99X6MPHJ5IA5T"0.C8.QG+LO&%HP3(?B!,:68 MI3SP@Q^+KO*?8H,AP!" -;"&^3(KQ2QL@OD^YXXGS-?^D;$82<$08 CL2S&+ MMV (\_KLUF$(K$8&5@B5M" ]$I;YT>0L5,*KD8/]P/]KDJ3*%]%8Q3+5D(AQ M')T'J3EI\$(Y,B#O-8+'ZD79NW\QJ$S+H=I:2T7"U[>=*IYM>'C%VN@YCVL-%L!,[[&0YDX.=/&TG;@7MM; 3V FP!M:P;ECW XD>K/O) MR&_3:32P%F0E/6/!@*(Y'#"@4;%])A M6&&4 MAM3A;KZ%6L H*<.,#1.AZ)3K<#=@0BV@Z)1AICI'1P!$G+C0!Y/.I0+48+0E M,%-U/+"7!@I0@]&6P(SH!.RU&.9\9TT! M:C#:$IBISH]+/UR*>O#1O;4CGM@(HR1Y+69?U:#]4J$;)1X:Q:-_=+N" T! M\&IA)F*,XI4YD(*Y99[?Q$.:ZROL\@:"TR XI!F0VL%4"$*9AR:Q<+R-9FW' M(.1I$ORU.0@3"4Q,,CNBI#5.E?.%)2146:]#H,K<"$YDTKPDS6@8*1C=]NA2 M?W@47PDY\L50CB;GLI].XNR:8Q7*[+2A_H7^WBHQ)Q6$@)C454+"(9T*=G0& MO_%P 4%8P5Z3>DR(J'/3(.#!;Z@S8 6L$ 53.TZ(F!Z6)-SX321.,0U6L->D M_A,BZKQK$/#@-^;.Z$8Q!N'V*)6C09#M22B31*5"#J,X#;[+-(C0C&*8;* 9 MI4#L=U:P1?";!K^IVB+8RP)F1CG*3FW/(.#!;Z@S8 6L$ 6TI*P1^SWT8++C M-\\PE C.C'&4'FY>PXS?5N3.Z4PI&^%,4^=^",)PVIP2W0Y5@.)9!/-1? MSYR($ J"UI2"L=\R"':P&\\96 LKV(O&%&BS90B;QFYH,V"U!U:( MI2"L;> MK:,OA1W!>>8I8"\1F!GE*6[-,PAX\!N39_2E&(/PB4K2>#+?WVL:JD3IA8I% M/TI2$2M?_RJ(1B(8!6D@T^!RA4V_D,W2R&8Y)2NK]'""WS3X3=4KP5X6,#/* M5IQ:W2#@P6^H,V %K! %-*NL]?8=EB3<^,TS7 %[B<#,*%S!DH0?OZG.G=&L M4C#"OT\TANF5B-50^<%J6WTAB:61Q/)*3_)W;H+?-/A-U0S!7A8P,TI/7#RE MRX[?4&? :@^L$ 7TIA2^),E_S#'X38/?/-,3L)<(S(S2$RQ)^/&;ZMP9K2D% M(WS0_V<2)$&6FFQF6WVI03R-4*9=*O.3Z,T)!:$>:$:I,$X!OVGPFZH[@KTL M8&84IVRLZ,1I2"$?X2I,$ _2<&:@3Z3PI]G"#_N8[@-PU^4_5 L)<%S(P" M$V^%^T?@-PU^0YT!JSVP0A30?U*XZ6%)PHW?/$,3L)<(S*Q"D_Q[*X+?-/A- M=>Z,_I.UA28B46D:JNQ<>3&00?X0!4$KC:"54XB2_P!CL)L&NZDZ(MC+ F9& M$0JTF1N[HSF&9^ O41@9A2?;#BUAD'(TR0X6N#- MB4[0;Y(/X=8DCL9*CL0?HRP^.59^T)>A.%*705^)$S68A.A&,= =T8U244J%CT+_0W4XDY.>$3)7CI3/^#OI37N5)$.4AX;/F/D^4:$HNJA&%1,/8S MCV5C"L9)$-S F%+, AZXP#5RL!_X M?TV25/DB&JM8IAH2,8ZC\R 5LR]K3AZ\4)4,SWOMX+&RP<%+;V8JI5XD+-YK M5O"$RT,>_Z#:8>@4C/V]'D_7;,0K@R0*=F+:F,@;SL%.#L),<*\'R M#W*"G51O)ZQ6*$MV,@L.WZ127ZS^F1]_ZD )E;^IZ MXT<4:5JU73WSN^BOS50XTX^KOWLCW(CH7WO2VU,\_O;N(?S!]H+;.8B7_ MWI+GJ8K?RO";O$JN1<1Q9DV@LS).BSJG]6\OG!>BK\(PTPT]"F[^/1\5TW_/ M!UQ?7[^*;T;7?%STHS"4XT2]O7ZQ+VY]ZG7\K/] ?XI^(W?W1;4&>/W-[B/) M["H+\ZDY#RY,_V\7'K1'QH=X];/?&Y^^6HW?ETNBG:G]]O^U1._@_\7)04^_Z(J#H__\ M<=IK'=WS:Y2NFM)][)[\^M)M.ON]SZWK%R>M^ZWC#ZWY^]2=3>$YGB/DR-[6]G8I[MI0];H7>XZ4]=P2D :AR<",+<[ 7HMA=FN-'%N< 6HPVA*8 MH<> U1Y8(0IEK3K<'/LL VHPVA*8H<=@K\4PN[5FCL-> #48;0G,5/48P0=U MYI8H$.6E>,:!G"OVH)"?&H<\Z WWLQ16S-T0@A"#&C!#CP$K8(4H( 0A##5@ MAAY;"RO8BQ"$&-2 &7IL40BRE'CPW:!XL=NI66VSD[=7J^<\08/<+?W>1:R4 M.-:_O$A$2W\/7YRJ<:J&9RJ^Z5ZK;@L$W-XO%%&IV)QA! MMB';/&2;\1R]6H;?"+U7\78$]>P1FU7W+>/A!-G.$E!ZDDK_+*+3M@*31,F; M/EH"5;I?E9:VN8$JV:]*),4$9FL!/[) 0%56N]T MLOF,8YJXJ%*5TTFHD@&JQ&_*E/NVY]K/%*?2G]DZ/U?]-+A4(I7_%;%,E4'G MMN?0?CSH5$(=O%SWFEFW3 MS=#=>F.%P_(@[\^#^;4Y"$/9 :DE0@W#-*,.7KZDA(=A.K6Z0:6!74+;;;-+ MZ+HA=7#S94T\=+VNEX4&U0;"#F%_YK&MV,NS.'A[\K]"3?.B[.A5Z?\U2=*A M_CJ)&$I?B3022L8C#4$BSI1^MVFFI))WR>3FLG]\Y]WM5_MA,%);%[,OZ'K. MJ_U+%:=!7X9S!=589'=E]$#1;_'>G,YOHH)D6H/]RMN(VNNX>Q6IA-*4V/+#PD@W-!8& 4^3 MWWC6@;QBT"2N<3 SBEVV#((=[(8V U; "E&HJN6&A>5A>P%^_(8Z@[T6P\PH M<\&"A!N[J6HSFF.*AG@A+9EMI99UP S-R0XA&.A9*19Z?:4&X0YZXPD$:V$% M>]&S4C#V;L/#$V+L& Y]!JSVP I10-=*P=AOK+)S#0B^[J>YH,R62@9-XAH' M,Z/P!.L1A@2G*L^E=ZR8<_YVF;AWTPL5B[Z*4QF,IK'*0E.+.2GA$P=B81_/ MJLZJ^3?5(&&Z[@H[UQ0K508>$L=@7."8.!,T"'9@3"F6S[=A[P=.K0D_8#0P MX ? FB+6\%X+2K%\5 Y[[]UP*S@M!^9;R>X#\ (3! A>8$PIEH_78>\%7LV! M%3 :&/"#2KJ.'DO-_&AR%BKAUK!LK05.1AW63MF[8B3UC(F\J M"#MYTDZJ.(D6=@([JO5 1$^IP M-VA#+:#HE&&&H@-6>V"%41I2A[NQ%FH!HZ0,,Q0=BDZY#G>3)=0"BDX99JJ* MOAP ]:-0TTA#[.Z^J);5CD, [7?)Y.;[__CPW>U7^V$P4EL7LT]R/7VMERI. M@[X,YR&ZOJAL2X/7[][HMW@OVJ-^./%5(H+1I;Z<*+X2V4E80SF:G,M^.HDS M$&,5RJPOK7^AD5#)OO[C5(X&0:;+,DE4*N0PTI_R7:9!--H7@RCROP5A.'VK M.W\;#,<_O!_ M)OI*TBO]ZZ'R@_E'ROX_DR )LG]L9A^I!O'T-]/WG'__?:'_OV P_S]^O!;Z M6Z6ARKZ1&,A _ZXUB:.QDB/QQRC[_;'^'(V@.%*705^)$S68A->?^^,KS\"Y M,P+>I%)?N_Z9'URN1+LEEKVZS;'%$?L#3>O9'O170NO&D7P,\_O;N( M?^C:0&V=Q4K^O27/4Q6_E>$W>97J5:R]_9N*?8"16;7 M6-A#07,2G$6AGY,VS^7(G^WCX]:)^-#N'K=ZXG/WRU&[\^ET4[0[AS5S)BG&>%/6U][K>,/6OSKSJ;P',^9SB*/6H?SG[K93]T]# 0,!*(#82,8"?U> MH5Y")9MB,I(37]/+-^A\(HZ4KQ+O[4;-(W!?QK2;B[B'6\X]7*?F- U&$T' MYMH.Y!CDM1-FR#$8C9FR90CS(7*%"SX[A)G"+0[3H >_,6NV%54FA%=>M>&5YTXE)<_Q(>0F@*=JG*KAF8I_?>DVG?WK MK+>Z;8 P_2L6T6RNQ_=,$*B,$4/@2/6G(E/=4R.<]"7W?&;M!W,1N0MXI,[2 M33UPTPO1G\295$Z?A0HC?Y0=V[JKER%^F<2:*3UUTF,ND6/0ZC-*,4M9_@WY2!A#AM[S9U:W9C]Y%F=0UU^BPKN M-E>O0# #8TH!,[AE!DUWIU;A77^80471P",+![I'C'14*GQUEAJU,,:Y573N M+N'(JGGM=C;KGK>"L10K:SBUJHK;XP\O->@ZBHU)!/RD\C+!3U;VDZ93KVW# M3XP0.;0S$K]-@@W-S:C#/3Z!6J#KAC3,')]0@J SJ0,$W9Q:+H :C,=>V%U60%W),"NK2&5WE1+G<$Y<>2F>R-[7JO*+MY?.*WKTYB_RK M[-BB-Q?I,-0O_@=02P$"% ,4 " "N-6915M7QS*$% #C' $ M @ $ >F)H+3(P,C Q,3 V+GAS9%!+ 0(4 Q0 ( *XU9E&T M<>7-A@8 (,Z 4 " <\% !Z8F@M,C R,#$Q,#9?9&5F M+GAM;%!+ 0(4 Q0 ( *XU9E'VL/N,8 D "%J 4 " M 8<, !Z8F@M,C R,#$Q,#9?;&%B+GAM;%!+ 0(4 Q0 ( *XU9E&0]?5A M2P8 +T] 4 " 1D6 !Z8F@M,C R,#$Q,#9?<')E+GAM M;%!+ 0(4 Q0 ( *XU9E%PR2W*&!, #2B 3 " 98< M !Z8F@M.&M?,C R,#$Q,#8N:'1M4$L! A0#% @ KC5F45S=&<#DY,5\V+FAT;5!+!08 ..!@ & ((! K*@$ ! end